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Summary 
Summary 
  To investigate mechanisms of the dendritic cell (DC) dysfunction during tumor 
progression, a transgenic murine model of spontaneous melanoma was used. Ret 
transgenic mice overexpress the human proto-oncogene ret in melanin containing 
cells and develop skin malignant melanoma which closely resembles human 
melanoma with respect to tumor genetics, histopathology and clinical development.  
Numbers of total DCs (MHCII+ CD11c+ cells) and mature DCs (DCs expressing 
CD40, CD80, or CD86) were found to be significantly decreased in the spleen, lymph 
nodes and bone marrow of tumor bearing mice as compared to ret transgenic tumor 
free or wild type mice (control groups). Moreover, tumors recruited more DCs during 
progression but the tumor infiltrating DCs were blocked at the immature stage. 
After stimulation in vitro, ex vivo isolated DCs or those generated from bone 
marrow precursors from tumor bearing mice produced significantly more IL-10 and 
less IL-12 than DCs from control mice, showing a tolerogenic cytokine pattern. DCs 
from tumor bearing mice displayed also significantly less capacity to stimulate CD8+ 
T cells to produce IFN-γ. Therefore, the phenotype and function of DCs in ret 
transgenic mice showed the characteristics of tolerogenic DCs. 
Melanoma-derived factors in ret transgenic mice were demonstrated to be involved 
in the acquisition of tolerogenic properties, since DCs generated from bone marrow 
precursors in medium supplemented with mouse melanoma cell conditioned medium 
produced significantly less IL-12. Moreover, when activity of VEGF, IL-6, or TGF-β 
was blocked with the respective neutralizing antibodies, IL-12 production by DCs was 
significantly upregulated.  
The p38 mitogen-activated protein kinase (MAPK) can be activated by different 
tumor-derived factors. A considerably elevated expression of the phosphorylated form 
of p38 MAPK was detected in DCs from tumor bearing mice. Suppression of p38 
MAPK activity in DCs from tumor bearing mice in vitro was found to lead to 
normalization of their cytokine expression pattern and T-cell stimulation capacity.  
Taken together, constitutive activation of p38 MAPK is responsible for turning of DCs 
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to display a tolerogenic profile in the process of melanoma development. We have 
demonstrated that suppression of the p38 MAPK activity in DCs from ret tumor bearing 
mice can reconstitute their impaired cytokine secretion pattern and ability to stimulate T 
cells suggesting thereby that such normalization of signaling pathways in DCs could 
represent an effective immunotherapeutic strategy in melanoma patients. 
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I. Introduction  
 
1. Immune system and antitumor immune response 
  The immune system defends host against infection. Serving as the first line of 
defense, innate immunity is essential for the control of common bacterial infections. 
However, it lacks the ability to recognize certain pathogens and to provide the specific 
protective immunity that prevents reinfection.  
  In the adaptive immune response, lymphocytes, which express diverse 
antigen-specific receptors, enable the immune system to recognize any foreign antigen. 
Besides eliminating pathogens, the adaptive immune response can generate increased 
numbers of memory lymphocytes, which allow a more rapid and effective reaction 
upon reinfection.   
 
1.1. Innate immunity 
Phagocytes 
  The phagocytic cells of the immune system include macrophages, neutrophils, and 
dendritic cells (DCs). Macrophages are large phagocytic leukocytes, which are able to 
move outside of the vascular system by moving across the cell membrane of capillary 
vessels and entering the areas between cells in pursuit of invading pathogens. In 
tissues, organ-specific macrophages are differentiated from phagocytic cells present in 
the peripheral blood called monocytes. Macrophages are the most efficient phagocytes, 
and can phagocytose substantial numbers of bacteria or other cells or microbes. The 
binding of bacterial molecules to receptors on the surface of a macrophage triggers it 
to engulf and destroy the bacteria through the generation of a “respiratory burst”, 
causing the release of reactive oxygen species. Pathogens also stimulate macrophages 
to produce chemokines, which summon other cells to the site of infection. 
  Neutrophils eosinophils and basophils are known as granulocytes due to the 
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presence of granules in their cytoplasm, or as polymorphonuclear cells due to their 
distinctive lobed nuclei. Neutrophil granules contain a variety of toxic substances that 
kill or inhibit growth of bacteria and fungi. Similar to macrophages, neutrophils attack 
pathogens by activating a respiratory burst.   
  DCs are phagocytic cells locate in tissues that are in contact with the external 
environment, mainly in the skin (where they are often called Langerhans cells), and in 
the inner mucosal lining of the nose, lungs, stomach and intestines. They are named 
for their resemblance to neuronal dendrites, but DCs are not connected to the nervous 
system. DCs are very important in the process of antigen presentation, and serve as a 
link between the innate and adaptive immune systems. 
 
Natural killer (NK) cells  
  As a component of the innate immune system, NK cells attack host cells that have 
been infected by microbes, but do not directly attack invading microbes. For example, 
NK cells attack and destroy tumor and virus-infected cells through a process known as 
"missing-self" (1). This term describes cells with low level expression of major 
histocompatibility complex (MHC) class I, a situation that can arise in viral infections 
of host cells. They were named "natural killer" because of the initial notion that they 
do not require activation in order to kill cells that are "missing self." 
 
Mast cells 
  Mast cells reside in the connective tissue and mucous membranes, and are 
intimately associated with defense against pathogens, wound healing, but are also 
often associated with allergy and anaphylaxis (2). When activated, mast cells rapidly 
release characteristic granules, rich in histamine and heparin, along with various 
hormonal mediators, and chemokines, or chemotactic cytokines into the environment.  
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Basophils and eosinophils 
  Basophils and eosinophils are cells related to the neutrophils. When activated by a 
pathogen encounter, basophils releasing histamine is important in defense against 
parasites, and plays a role in allergic reactions such as asthma. Upon activation, 
eosinophils secrete a range of highly toxic proteins and free radicals that are highly 
effective in killing bacteria and parasites, but are also responsible for tissue damage 
occurring during allergic reactions.  
 
γδ T-cells 
  Like other 'nonconventional' T-cell subsets bearing invariant T-cell receptors (TCRs) 
such as CD1d-restricted NK T cells, γδ T cells exhibit characteristics that place them 
at the border between innate and adaptive immunity. On one hand, γδ T cells may be 
considered as a component of adaptive immunity since they rearrange TCR genes to 
produce junctional diversity and develop a memory phenotype. On the other hand, 
they may function as a part of the innate immune system where a restricted T-cell or 
NK receptors may be used as a pattern recognition receptor.  
 
Complement 
  The complement system is a biochemical cascade of the immune system that helps 
or “complements” the ability of antibodies to clear pathogens or mark them for 
destruction by other cells. The cascade is composed of many plasma proteins, 
synthesized in the liver, primarily by hepatocytes. The proteins work together to 1) 
trigger the recruitment of inflammatory cells; 2) "tag" pathogens for destruction by 
other cells via opsonizing the surface of the pathogen; 3) disrupt the plasma 
membrane of an infected cell, resulting in cytolysis of the infected cell, causing the 
death of the pathogen; 4) rid the body of neutralized antigen-antibody complexes.  
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1.2. Adaptive immunity 
CD8+ T lymphocytes 
  Cytotoxic T cells (CTL, CD8+ T cells) are a subgroup of T cells, which induce the 
death of cells that are infected with viruses (and other pathogens), or are otherwise 
damaged or dysfunctional. Naive CD8+ T cells are activated when their TCR strongly 
interacts with a peptide-bound MHC class I molecule. This affinity depends on the 
type and orientation of the antigen/MHC complex and keeps the CTL and infected 
cell bound together. Once activated, the CD8+ T cell undergoes a process called clonal 
expansion, in which it gains functionality and divides rapidly into effector cells. 
Activated CD8+ T cells will then travel throughout the body in search of cells bearing 
that unique MHC class I peptide. 
  When exposed to these infected or dysfunctional somatic cells, effector CD8+ T 
cells release perforin and granulysin, which form pores in the target cell plasma 
membrane allowing ions and water to flow into the infected cell and causing it to 
burst or lyse. CD8+ T cells release granzyme, a serine protease that enters cells via 
pores to induce apoptosis. To limit extensive tissue damage during an infection, CD8+ 
T cells activation is tightly controlled. 
  Upon resolution of the infection, most of the effector CD8+ T cells die and are 
removed away by phagocytes, but a few of these cells are retained as memory cells. 
Upon a later encounter with the same antigen, these memory cells quickly 
differentiate into effector cells, dramatically shortening the time required to mount an 
effective response. 
 
T helper (TH, CD4+ T) cells  
  CD4+ T cells are immune response mediators and play an important role in 
establishing and maximizing the capabilities of the adaptive immune response. These 
cells have no cytotoxic or phagocytic activity and can not kill infected cells or clear 
pathogens as CD8+ T cells, but they can direct other cells to perform these tasks. 
  CD4+ T cells express TCRs that recognize antigen bound to major 
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histocompatibility complex (MHC) class II molecules. The activation of a naive CD4+ 
T cell causes it to release cytokines, which influences the activity of many cell types. 
CD4+ T cells require a much milder activation stimulus than CTLs and can provide 
extra signals that "help" to activate cytotoxic cells. 
  Two types of effector CD4+ T cell responses can be induced by a professional 
antigen-presenting cell (APC) designated as TH1 and TH2 each designed to eliminate 
different types of pathogens. The TH1 response is characterized by the production of 
interferon (IFN)-γ, which activates the bactericidal activities of macrophages, induces 
B cells to make opsonizing antibodies and leads to cell-mediated immunity. The TH2 
response is characterized by the release of interleukin (IL)-4, which results in the 
activation of B cells to make neutralizing antibodies, leading to humoral immunity. 
Generally, TH1 responses are more effective against intracellular pathogens (viruses 
and bacteria that are inside host cells), while TH2 responses are more effective against 
extracellular bacteria, parasites and toxins. Like CTLs, most of the CD4+ T cells die 
upon resolution of infection with a few remaining as CD4+ memory T cells. 
 
Regulatory T cells (Tregs) 
  Tregs may control aberrant immune responses to self-antigens, in particular the 
development of autoimmune diseases, such as type 1 diabetes, and some chronic 
inflammatory diseases like asthma. However, Tregs also block beneficial responses by 
preventing sterilizing immunity to certain pathogens and limiting antitumor immunity 
(3). Accumulation and activation of Tregs was reported in both tumor patients and 
tumor animal models (4-8). From the functional perspective, the various potential 
suppression mechanisms used by Tregs can be grouped into four basic ‘modes of 
action’: 1) suppression by inhibitory cytokines like IL-10, IL-35 and TGF-β; 2) 
suppression by cytolysis via granzymes and perforin; 3) suppression by ‘metabolic 
disruption’ of effector T cells through adenosine or cyclic AMP; 4) suppression by 
modulation of DC maturation and function (9).  
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APCs 
  Host's cells express "self" antigens. These antigens are different from those on the 
surface of bacteria ("non-self" antigens) or on the surface of virally infected host cells 
(“missing-self”). The adaptive response is triggered by recognizing non-self and 
missing-self antigens. 
  With the exception of non-nucleated cells (including erythrocytes), all cells are 
capable of presenting antigen and of activating the adaptive immune response. Some 
cells are specially equipped to present antigen, and to prime naive T cells. DCs, 
macrophages and B cells are equipped with special immunostimulatory receptors for 
activation of T cells and are termed professional APCs.  
 
B cells 
  B cells are major cells involved in the creation of antibodies that circulate in blood 
plasma and lymph known as humoral immunity. Antibodies (or immunoglobulins, Ig), 
are large proteins used by the immune system to identify and neutralize foreign 
objects. In mammals, there are five types of antibody, namely IgA, IgD, IgE, IgG, and 
IgM, which differ in biological properties. Upon activation, B cells produce 
antibodies, each of which recognizes a unique antigen and neutralizes specific 
pathogens. 
  Like the T cells, B cells express a unique B cell receptor (BCR), which recognizes 
and binds to only one particular antigen. A critical difference between B cells and T 
cells is how each cell "sees" an antigen. T cells recognize their cognate antigen as a 
peptide in the context of an MHC molecule, while B cells recognize antigens in their 
native form. Once a B cell encounters its specific antigen and receives additional 
signals from TH2 cells, it further differentiates into an effector cell, a plasma cell. 
  Plasma cells are short lived cells (2-3 days), which secrete antibodies. These 
antibodies bind to antigens, making them easier targets for phagocytes, and trigger the 
complement cascade. About 10% of plasma cells will survive to become long-lived 
antigen specific memory B cells. Already primed to produce specific antibodies, these 
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cells can be called upon to respond quickly if the same pathogen re-infects the host. 
   
1.3. Evidences of antitumor immunity in animal models and cancer 
patients 
  The idea that the immune system may have a protective role during tumor growth 
was embodied in the cancer immunosurveillance hypothesis of Burnet and Thomas 
(10, 11). Large amount of data obtained from animal experiments demonstrated that 
the immune system was capable of recognizing and eliminating primary tumors and 
that lymphocytes and cytokines produced by these cells were important in the process. 
In humans, early follow-up studies of transplant patients who were 
immunosuppressed (12) and individuals with primary immunodeficiencies (13) 
showed that they had a significantly higher risk of cancer development. A review of 
data accumulated by the Cincinnati Transplant Tumor Registry from 1968 to 1995 
found a two fold greater risk in transplant patients for developing melanoma than that 
of the general population (14). In Australia and New Zealand, the tracking of 925 
patients who received renal transplants from 1965 to 1998 showed an increased risk of 
the development of colon, pancreatic, lung and endocrine tumors as well as malignant 
melanomas (15). In addition, assessment of 5,692 renal transplant patients from 1964 
to 1982 in Finland, Denmark, Norway and Sweden showed higher standardized 
cancer incidence ratios for colon, lung, bladder, kidney, ureter and endocrine tumors 
as well as malignant melanomas as compared with the general population (16).  
  A positive correlation between the presence of lymphocytes in the tumor and 
increased patient survival has also been shown by numerous studies (17-20). One of 
the most convincing evidence came from the study of cutaneous melanomas. Sorting 
more than 500 patients with primary melanoma who had 5-, 8- or 10-year follow-ups 
and comparing their survival statistics, it was shown that patients with tumor 
infiltrating lymphocytes survived 1.5-3 times longer than patients without tumor 
infiltrating lymphocytes (21). Similar correlations between the presence of tumor 
infiltrating lymphocytes and patient survival have been made that involved more than 
3,400 patients with cancer of the breast, bladder, colon, prostate, ovary or rectum 
cancer and for neuroblastoma (17-25). In some cases, the correlation has been refined 
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to show that CD8+ T cells are the relevant lymphocyte population that affects survival 
(20).   
  However, the immune surveillance in tumor patients is mostly insufficient to 
control tumor growth, which is attributed to tolerance induced by many cells and 
soluble factors, such as regulatory T cells, myeloid derived suppressor cells (MDSCs), 
immunosuppressive cytokines and growth factors derived from tumor and host cells, 
and dysfunctional NK cells and DCs. 
 
2. Dendritic cells  
DCs engulf exogenous pathogens, such as bacteria, parasites or toxins in the tissues 
and then migrate, via chemotactic signals, to the T-cell enriched lymph nodes. During 
migration, DCs undergo a process of maturation in which they lose most of their 
ability to engulf other pathogens and develop an ability to communicate with T cells. 
DCs use enzymes to chop the pathogen into antigens. In the lymph node, DC will 
display these "non-self" antigens on their surfaces by coupling them to a 
"self"-receptor called the MHC (also known in humans as human leukocyte antigen 
(HLA). This MHC:antigen complex is recognized by T cells passing through the 
lymph node. Exogenous antigens are usually displayed on MHC class II molecules, 
which activate CD4+ TH cells. Endogenous antigens are produced by viruses 
replicating within a host cell. The host cells use enzymes to digest virally associated 
proteins, and display these pieces on their surfaces to T cells by coupling them to 
MHC. Endogenous antigens are typically displayed on MHC class I molecules, and 
activate CD8+ cytotoxic T cells.  
Binding of MHC:antigen complex by TCR does not stimulate on its own the 
proliferation and differentiation of naive T cells into armed effector T cells. The 
antigen-specific clonal expansion of naive T cells requires a second or costimulatory 
signal, which is delivered by binding of CD80/CD86 on DCs to CD28 on T cells. 
CD40 is also a costimulatory molecule which binds to CD40 ligand (CD40L) on T 
cells, transmits signals to the T cell, activates DCs to express CD80 and CD86, and 
thus stimulates further T-cell proliferation. Costimulatory signals promote not only 
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transcription of IL-2 but also stabilize IL-2 mRNA. An autocrine mechanism is used 
by IL-2 to stimulate T-cell proliferation. In contrast, antigen recognition in the 
absence of costimulation leads to T-cell anergy, a state in which T cells are unable to 
produce IL-2 (26). In recent year, a cytokine profile secreted by DCs has been 
described as a “third signal” (27). For example, naive CD4+ T cells stimulated in the 
presence of IL-12 tend to develop into TH1 cells, whereas environmental IL-10 drives 
the generation of Tregs (28). It means that these three DC-derived signals together 
determine the stimulation or anergy of naive CD8+ T cells and the development of 
TH1, TH2 cells or Tregs. 
Different DC subsets are generated from different precursor cells. For example, 
myeloid DCs (MDCs) are differentiated from common myeloid precursors (CMPs), 
whereas plasmacytoid DCs (PDCs) are from common lymphoid precursors (CLPs). 
MDCs are the main IL-12 producer (26) and the most efficient APCs able to prime 
directly naïve T cells and can be immunogenic or tolerogenic under different 
conditions (29). It is assumed that MDCs are important for the induction of the 
specific cytotoxic T-cell responses as well as TH1 polarized responses which are more 
efficient in anti-tumor immune response (30). De Vries et al. demonstrated that for the 
generation of an effective antimelanoma T-cell response, high numbers of sufficient 
activated MDCs are essential (31). Moreover, local priming of melanoma-specific 
CD8+ T cells, in stage I melanoma patients is associated with a high MDC content in 
the sentinel lymph node (32).  
  PDCs can produce large amounts of type I IFNs in response to viruses and other 
pathogens. Under steady-state conditions, PDCs appear to play a key role in 
maintaining peripheral immune tolerance, and may be considered as naturally 
occurring tolerogenic DCs (26). For example, activating-PDC-TLR ligands 
upreguated the expression of inducible costimulator ligand (ICOS-L), which led to the 
generation of IL-10 producing T regulatory cells (33). However, if stimulated with 
microbial pathogens, PDCs differentiate into potent APCs with type I IFN production 
capacity (34, 35). After viral stimulation, murine PDCs take part in both innate and 
adaptive immune responses by directly priming naive CD8+ T cells in vivo (36). 
Zuniga et al. reported that bone marrow PDCs can differentiate into MDCs upon virus 
infection (37). Moreover, PDCs help other DC subsets to induce T-cell responses. It 
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has been demonstrated that PDCs synergize with MDCs in the induction of 
antigen-specific antitumor immune responses in vivo (38). PDCs can also improve the 
activity of lymph node DCs to stimulate CTLs (39). 
 
3. Tolerogenic dendritic cells and tumor escape 
  Numerous clinical studies reported a dramatic decrease in DC numbers in the 
peripheral blood of patients with different types of tumors such as squamous cell 
carcinoma of the head and neck, lung cancer, myeloma, invasive breast cancer, 
hepatocellular carcinoma and leukemia (40-46). Moreover, the presence of metastases 
resulted in a more profound decrease in numbers of circulating peripheral blood DCs 
in cancer patients (46, 47).  
  Furthermore, impaired capacity of DCs to prime effective antitumor responses has 
also been observed, which is due to the lack of an efficient immune synapse between 
DCs and T cells (48).  
 
3.1 Generation of tolerogenic dendritic cell  
  DC functions in tumor patients are quite often found to be abnormal and such DCs 
induce normally immune tolerance to tumor cells. Therefore, understanding the 
mechanism of the generation of tolerogenic DCs in tumor progression will benefit the 
current immunotherapies in particular DC vaccination in tumor patients.  
 
3.1.1. Alteration of DC functions in cancer 
  Tumor cells can directly modulate DC function through different mechanisms, 
among which an induction of DC apoptosis and a blockade of DC differentiation are 
mostly investigated.  
  Tumor induced DC apoptosis has been reported to be mediated by cytochrome c 
release, which further leads to cytoplasm shrinking, caspase-3 activation, upregulation 
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of pro-apoptotic protein Bax and down-regulation of anti-apoptotic proteins Bcl-xL 
and Bcl-2 (49-51). Furthermore, growth of RM-1 prostate cancer cells could be 
significantly inhibited in mice treated intratumorally with DCs which were transduced 
with murine Bcl-xL gene (50). Other anti-apoptotic molecules are also shown to be 
able to inhibit tumor-mediated DC apoptosis, such as Fas associated death domain 
(FADD)-like ICE inhibitory proteins (FLIP) which blocks binding of procaspase-8 to 
FADD (52). 
   Numerous studies have shown that DCs in tumor patients or tumor animal models 
are phenotypically or functionally immature. CD83+ DCs obtained from progressing, 
chemotherapy-resistant melanomas revealed a marked downregulation of CD86 
expression and induced syngeneic CD4+ T-cell anergy (53). In breast cancer, DCs 
failed to stimulate proliferation of allogeneic T cells (54). Human basal cell carcinoma 
associated DCs were deficient in CD80 and CD86 expressions as well as in their 
ability to stimulate T-cell proliferation (55). Moreover, DCs isolated from human 
non-small cell lung cancer were blocked at immature stage (56). Similar data have 
also been shown in patients, such as multiple myeloma, colon carcinoma, head and 
neck cancer, and lung cancer (57-59). 
  Tumors can also affect the process of DC differentiation from their precursor cells. 
DCs derived from monocytes of myeloma patients expressed significantly lower 
levels of CD40, CD80, and HLA-DR and were not able to activate alloreactive and 
autologous antigen-specific T cells (60). In vitro studies showed that myeloma cells or 
myeloma cell conditioned medium could inhibit differentiation and function of 
murine bone-marrow derived DCs (61). The blockade of DC differentiation at the 
level of immature myeloid cells, an immune suppressive population, which comprises 
of immature macrophages, granulocytes, DCs and myeloid cells at early stages of 
differentiation has been found in a large number of different tumors including breast, 
lung, and head and neck cancer (40).   
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3.1.1. Tumor-derived factors and impairment of DC functions in cancer 
  In addition to the modulation of DC functions induced by tumors through cell-cell 
contact, tumors produce several immunosuppressive factors, which can also affect DC 
functions.  
 
TGF-β 
  TGF-β is involved in the regulation of numerous processes including hematopoiesis, 
cell proliferation, differentiation and activation (62). It is also known as the most 
potent immunosuppressive cytokine described to date. TGF-β can be secreted by 
many types of tumor cells. It is associated consistently with an aggressive tumor 
phenotype. For example, transfection of a regressor skin tumor cell with the gene for 
TGF-β enabled evasion of immunological destruction resulting in tumor progression 
in vivo (63). By modulating activity of NK cells, T cells, macrophages, and DCs, 
TGF-β affects initiation and effetor phases of both primary and secondary immune 
responses (64).  
Mechanisms of TGF-β in regulating DC functions have been described in several 
studies. Although it has been shown that TGF-β promoted the generation of 
Langerhans cells (65), data from most studies demonstrated TGF-β as a negative 
regulator for the immunogenic function of DCs. TGF-β induced the generation of 
DCs with an immature phenotype both in human and murine studies (66, 67). When 
added to LPS-stimulated DC culture, TGF-β inhibited the expression of MHC class II 
and costimulatory molecules on DCs (69). In addition, TGF-β could also suppress DC 
maturation and IL-12 production induced by IL-1 and TNF-α but not by CD40 ligand 
or anti-CD40 antibody (69, 70). Moreover, Byrne et al. showed that TGF-β producing 
progressive tumor recruited tumor infiltration of macrophages while the number of 
tumor-infiltrating DCs decreased, altering thereby proportion of APCs in favor of 
macrophages that enables tumor evasion of the host immune system (68).  
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IL-10 
  Various tumor cells express and release IL-10. This cytokine is also produced by 
tumor-infiltrating lymphocytes and macrophages (71). DC dysfunction in tumor 
bearing mice was shown to be induced by tumor-derived IL-10, whereas improvement 
of DC function was observed in tumor-bearing IL-10-deficient mice (72). IL-10 can 
convert immature DC into tolerogenic DC through decreased expression of 
costimulatory molecules (73). Moreover, DCs derived from transgenic mice which 
overexpress IL-10 markedly suppressed allogeneic T-cell responses and IL-12 
production (74). Human DCs generated from CD34+ hematopoietic progenitors were 
sensitive to IL-10 treatment at all stages of differentiation and IL-10 inhibited the 
primary and secondary proliferative responses of both CD4+ and CD8+ T cells 
induced by allogeneic CD1a+ DCs (75). Steinbrink et al. reported that IL-10-treated 
human DCs induced CD4+ and CD8+ T cells that suppressed antigen-specific 
proliferation of other T cells (76). Notably, IL-10 worked also as a mediator of 
prostaglandin E2 (PGE2), which could suppress IL-12 production by DCs (77). 
Finally, IL-10 was reported to skew the differentiation of monocytes into 
macrophages instead of DCs (78). 
 
Vascular endothelial growth factor (VEGF) 
  VEGF is produced by most tumors and promotes tumor development, in particular 
tumor angiogenesis (79). A correlation between VEGF expression and microvessel 
density could be observed in many malignancies (79). Increased plasma levels of 
VEGF were reported in tumor patients compared with healthy donors; high VEGF 
levels were associated with a poor outcome in small cell lung carcinoma and breast 
cancer patients (80-82). Production of VEGF by human tumors inhibits the functional 
maturation of DCs from precursors and affects the function of relatively mature DCs 
(83). Saito et al. reported an inverse correlation between the DC density and the 
VEGF expression within tumor tissue and peripheral blood of cancer patients (84).  
  The role of tumor-derived VEGF in DC differentiation have been demonstrated by 
in vitro experiments, in which neutralizing antibody against VEGF abrogated the 
negative effect of tumor cell conditioned medium on DC differentiation from their 
20 
Introduction 
precursors (83), and the in vivo data further confirmed this conclusion (85). Moreover, 
continuous infusion of VEGF into naïve animals resulted in a dramatic inhibition of 
DC development and an increase in numbers of B cells and immature myeloid cells 
(85). Consistent with these observations, administration of neutralizing 
VEGF-specific antibody to tumor-bearing mice improved DC differentiation and 
increased the number of mature DCs (86, 87). Furthermore, an inhibitory effect of 
VEGF on DC differentiation has been shown in patients with gastric cancer or 
non-small-cell lung cancer (88). 
Mechanism of VEGF-induced DC dysfunction remains unclear. More recent 
studies indicated that VEGF receptor 1 is the primary mediator of the VEGF 
inhibition of DC maturation (89), whereas VEGF receptor 2 is crucial for early 
hematopoietic differentiation, and only marginally affects final DC maturation. 
Although several inhibitors of VEGF receptors are undergoing clinical trails (90), a 
recent study showed that the defective differentiation of DCs in advanced cancer 
patients could not be normalized by blocking VEGF signaling through VEGF receptor 
inhibitors (88). 
 
IL-6 
  IL-6 is a pleotropic cytokine that can be produced by several malignant tumors (91). 
In plasmocytoma and chronic lymphatic leukemia patients who showed 
overproduction of IL-6, the development and functional maturation of DCs was 
impaired (92). In the recent study, IL-6 was found to suppress DC maturation in vivo 
(93). 
  IL-6 skewed in vitro differentiation of monocytes into phenotypically mature but 
functionally impaired DCs and inhibited the chemotactic response of DCs through 
blocking the upregulation of CCR7 expression on their surfaces (94). IL-6 secreted by 
stroma cells upregulated the expression of macrophage-colony stimulating factor 
(M-CSF) receptors on monocytes, and together with M-CSF, it could directed 
monocyte differentiation rather to macrophages than to DCs (95). Involvement of 
IL-6 in the inhibition of DC differentiation has also been shown in multiple myeloma 
patients (53). Human renal cell carcinoma cells released large amounts of M-CSF and 
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IL-6, which inhibited myeloid progenitor cell to differentiate into DCs (96). 
Bharadwaj et al. reported that IL-6 and G-CSF in human pancreatic cancer cell 
conditioned medium are responsible for the suppression of DC differentiation, 
maturation, and antigen presentation due to the aberrant activation of STAT3 (97). 
 
M-CSF 
  The inhibition of DC differentiation by renal-cell carcinoma cells conditioned 
medium was preceded by inducing M-CSF receptor and losing 
granulocyte-macrophage colony stimulating factor (GM-CSF) receptor α expression 
at the surface of CD34+ cells (96). Interestingly, IL-4 and IL-13 could reverse such 
inhibitory effect of IL-6 and M-CSF on the phenotypic and functional differentiation 
of CD34+ cells into DCs (98). The protecting effect of IL-4 on DC differentiation was 
found to be due to the down-regulation of M-CSF receptor on surface of DC 
progenitors, the decrease in M-CSF production, and the maintenance of GM-CSF 
receptor α expression. 
 
GM-CSF 
  In the physiologic situation, GM-CSF is required for normal myelopoiesis and DC 
differentiation. However, excessive amounts of GM-CSF can mediate 
immunosuppression via induction of tolerogenic DCs and immature myeloid cells (99, 
100, 104). Gaudreau et al. reported that GM-CSF could prevent diabetes development 
in NOD mice by inducing tolerogenic DCs, which sustain the suppressive function of 
CD4+ CD25+ regulatory T cells (99). Chronic administration of GM-CSF to mice 
resulted in the generation of immunosuppressive Gr-1+ CD11b+ cell population which 
resembled morphology of granulocyte-monocyte progenitors (100). These cells could 
further differentiate to fully mature APCs in the presence of IL-4 and GM-CSF.  
  In mice bearing Lewis lung carcinoma, the administration of anti-GM-CSF and 
anti-IL-3 antibodies abrogated the accumulation of tumor-induced immune 
suppressive granulocyte/macrophage progenitor cells (101). Interestingly, GM-CSF 
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has shown its therapeutic potential as a component of cancer vaccines (102). In a 
randomized trial in patients with high-risk melanoma, GM-CSF treatment was 
associated with a transient increase in mature DCs (103). However, it seems that 
production of large amounts of GM-CSF by some tumors is detrimental to the host 
immune system. Serafini et al. (104) showed that vaccination of mice with tumor cells 
producing large amounts of GM-CSF generated a large number of Gr-1+ 
immunosuppressive cells which consequently have a negative impact on vaccination. 
 
3.1.3. Role of regulatory T cells in the impairment of DC functions in cancer 
  It has been reported that the co-culture of mouse CD4+ CD25+ Tregs with mouse 
bone marrow-derived DCs prevented upregualtion of costimulatory molecules and 
resulted in downregulation of DC-mediated T-cell function (105). In vivo, the function 
of mature DCs is also under the control of naturally occurring CD4+ CD25+ Tregs. 
Thus, depletion of CD4+ CD25+ Tregs enhanced the development of MHC class I and 
II restricted IFN-γ producing cells and induced higher cytotoxic activity of CD8+ T 
cells (106). In a murine melanoma model, depletion of CD4+ CD25+ Tregs elicited 
long-lasting protective tumor immunity induced by DCs loaded with stressed tumor 
cells (107). In humans, the coculture of CD4+ CD25+ Tregs with monocyte-derived 
DCs rendered DC inefficient as APCs despite of their prestimulation with CD40 
ligand. Moreover, DCs cultured with Tregs were prevented from maturation (108) and 
produced more IL-10 (109). Accumulation of immunosuppressive DCs and regulatory 
T cells has been found in melanoma and other tumor patients (110). In the peripheral 
blood of patients with squamous cell carcinoma of the head and neck, expression 
levels of HLA-DR on myeloid and total DCs positively correlated with the ratios of 
TH1 and TH2, and the percentage of total circulating DCs inversely correlated with 
that of CD4+ CD25+ Tregs (111).  
Although the cellular and molecular events that play a role in the DC regulation by 
CD4+ CD25+ Tregs are still not completely clear, it seems that cell-cell contacts and 
immunoregulatory cytokines are involved. For example, CTLA-4 on CD4+ CD25+ 
Tregs could upregulate indoleamine 2,3-dioxygenase (IDO) expression in DCs (112). 
Larmonier et al. (113) demonstrated that CD4+ CD25+ Tregs derived from a leukemia 
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mouse model suppressed DC functions, which required TGF-β and IL-10 and was 
associated with induction of Smad signaling pathway and activation of STAT3. 
 
3.1.4. Transcription factors in tolerogenic DCs 
STAT3 
  STAT3 was found to be activated in diverse cancers (114). Constitutively activated 
STAT3 enhanced tumor cell proliferation and prevented apoptosis (115). Inactivation 
of STAT3 by certain platinum compounds inhibited tumor cell growth and induced 
apoptosis (115). It is important to note that constitutive STAT3 activity in tumors 
induced the release of factors such as VEGF and IL-10 that inhibited DC maturation 
through activation of STAT3 in DCs (116). Inhibiting STAT3 signaling in DC 
progenitors has been shown to reduce accumulation of immature DCs by 
tumor-derived factors in vitro (117). Ablation of STAT3 in hematopoietic cells 
enhanced DC maturation in tumor-bearing mice and resulted in a multicomponent 
antitumor immunity (118). 
 
Extracellur signal regulated kinase-1/2 mitogen-activated protein kinase (Erk 1/2 
MAPK) 
  Erk, a member of MAPK family, regulates essential cellular functions like 
proliferation, differentiation, cell survival, and cell death (119, 120). Constitutive 
activation of Erk pathway has been described in cell lines derived from pancreas, 
colon, lung, ovary, and kidney cancers (120). In melanoma, Erk1/2 activation was 
observed in 54% of primary and 33% of metastatic melanomas (121). Furthermore, 
Erk protected melanoma cells from cisplatin-mediated apoptosis and was shown to be 
essential for melanoma-immune evasion (122,123).  
  Activation of Erk in DCs has been demonstrated to promote IL-10 production and 
mediated negative feedback regulation of IL-12 production (124). Moreover, Jackson 
et al. (125)vshowed that melanoma lysate could suppress IL-12 production by DCs 
through activating Erk1/2 MAPK in DCs and blockade of Erk1/2 activation restored 
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IL-12 production and generation of TH1 cells by DCs. Inhibition of Erk function could 
also promote the phenotypic and functional maturation of murine resident Langerhans 
cells (126).  
 
p38 MAPK 
  A significant role of p38 MAPK has been reported in several types of tumors, such 
as follicular lymphoma, chronic B cell lymphocytic leukemia, and melanoma 
(127-129). Activation of p38 in malignant B lymphoma cells upregulated IL-10 gene 
expression and promoted lymphomagenesis (130). In addition, human malignant 
glioma cells secret high level of VEGF through constitutive activation of p38 MAPK 
(131).    
  It was reported that blocking p38 MAPK pathway could significantly up-regulate 
IL-12 production in mature DCs (132, 133). Wang et al. (60) reported that the 
impaired function of monocyte-derived DC from multiple myeloma patients could be 
restored by inhibiting p38 MAPK in progenitor cells. In addition, inhibition p38 
MAPK activity in the bone marrow (BM) cells cultured in the presence of tumor 
culture conditioned medium restored the generation of functional BMDCs (61). 
Importantly, regulatory T-cell induction could be attenuated by inhibiting p38 MAPK 
signaling in DCs (134).  
 
3.2. Tolerogenic DCs induce T-cell tolerance 
  DC maturation in tumor patients is often blocked at the immature stage which may 
tolerize peripheral CD4+ and CD8+ T cells by inducing deletion, anergy or regulation 
(135-138). This was attributed to the lack of costimulatory molecules on DC surface. 
  However, the CD80 and CD86 molecules could also limit the activation of T cells 
by binding with CTLA4 expressed on T cells. In these DCs, activity of indoleamine 
2,3-dioxygenase (IDO) was upregulated by the autocrine secretion of IFN-γ following 
the engagement of CD80/CD86 by CTLA4 (139). IDO is an enzyme that exists in 
DCs within mouse and human lymphoid tissues and catalyzes the depletion of the 
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essential amino acid tryptophan, resulting in the inhibition of T-cell proliferation and 
produces tryptophan-derived metabolites that promote T-cell apoptosis (140). In mice, 
PDCs could downregulate T-cell responses through the upregulation of IDO (141). 
Moreover, Baban et al. have characterized a small subpopulation of DCs in mouse 
spleen that synthesized large amounts of IDO and downregulate T-cell function (142). 
Such IDO+ CD19+ DCs increased IDO production following CD80/CD86 ligation by 
CTLA4 or TLR9 ligation.  
In addition, a role of B7-H1 and B7-H4 molecules (inhibitory members of B7 
family) on DCs has been recently studied. Investigations in patients with breast cancer, 
colon cancer, melanoma and multiple myeloma showed that the overexpression of 
B7-H1 and B7-H4 led to the inhibition of T-cell function and was associated with 
poor prognosis (143). Furthermore, MDCs in human tumors and tumor-draining 
lymph nodes expressed a high level of B7-H1 (144, 56). The interaction between 
B7-H1+ MDCs and tumor-associated T cells led to the downregulation of IL-12 and 
upregulation of IL-10 production by MDCs in a B7-H1-dependent manner. Blockade 
of B7-H1 on tumor-infiltrating MDCs resulted in the increase of IFN-γ production by 
T cells (144). Adoptive transfer of such T cells improved the clearance of human 
tumors in xenotransplanted mice, supporting the idea that B7-H1 plays a role in the 
downregulation of DC-mediated tumor immunity (144).   
 
3.3. Tolerogenic DCs induce the differentiation of TH2 cells or Tregs  
  Steinman et al. reported that immature DCs may maintain the immune tolerance by 
inducing TH2 response (145). In cancer patients, the TH1 skewing has been correlated 
with improved clinical outcomes (146-148). Investigations on tumor-specific T-cell 
immunity in renal cell carcinoma (RCC) and melanoma patients have demonstrated 
that patients with active melanoma or RCC displayed strongly polarized TH2-type 
reactivity, whereas healthy donors and patients that were disease-free following 
therapeutic intervention exhibited either weak mixed TH1/TH2 or strongly-polarized 
TH1 (146).  
  Immature DCs may also induce expansion of IL-10 producing Treg (Tr1) and CD4+ 
CD25+ Tregs (149-151). Furthermore, tumor-associated immature DCs induced CD4+ 
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CD25+ Tregs from naïve T cells, and suppress T-cell proliferation of both CD4+ and 
CD8+ T cells (152). It has been shown that DCs induced Tr1 through IL-10 (149, 153, 
154). Finally, TGF-β secreted by a DC subpopulation has also been implicated in the 
generation of CD4+ regulatory T cells (155).  
 
4. Malignant melanoma 
  Melanoma is a malignant tumor due to the uncontrolled growth of transformed 
melanocytes, which are found predominantly in skin but also in the bowel and the 
eye.  
 
4.1. Epidemiology and diagnosis 
4.1.1. Risk factors  
  Major risk factors for melanoma development include excessive sun exposure, 
number of melanocytic nevi, cutaneous phenotype, and family history of melanoma. 
Unlike the more common skin cancers that are associated with high cumulative doses 
of ultraviolet light, most melanomas appear to be associated with intense, intermittent 
exposure, particularly during childhood and adolescence.  
  Epidemiologic studies have repeatedly shown an increased risk of melanoma in 
persons with large numbers of melanocytic nevi (156). Individuals with clinically 
atypical or "dysplastic" nevi have a higher risk, particularly in the setting of a positive 
family history of melanoma. In one study, the risk of melanoma was double in 
individuals with 50 to 99 small nevi compared to those with less nevi’s numbers (157). 
About 10% of all melanoma patients have a positive family history. Genetic linkage 
studies have identified a gene CDKN2 on chromosome 9p21, which encodes the 
tumor suppressor protein p16 and is involved in melanoma development. Mutations in 
this gene have been documented in 50% of familial melanoma patients (158).  
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4.1.3. Clinical presentation, diagnosis, and prognosis  
  Melanoma generally arise from preexisting nevi and demonstrate asymmetry, 
pigment variegation, and irregular borders. Nodular melanomas are the second most 
common form of melanoma. They may be evenly pigmented and have regular borders 
and be easily mistaken for a basal cell carcinoma, seborrheic keratosis, or a benign 
nevus. Lentigo maligna melanoma occurs on sun-exposed skin, especially the face of 
elderly patients. In contrast to superficial spreading and nodular melanomas, this 
subtype is associated with high cumulative doses of the ultraviolet light. They tend to 
grow slowly and often are confined to the epidermis (lentigo maligna) for years before 
dermal invasion occurs (lentigo maligna melanoma). 
  The prognosis of melanoma is related to tumor thickness. Melanoma that is 
confined to the epidermis (in-situ) is greater than 99% curable, and patients with thin 
lesions (< 0.75 mm) have a 5-year survival rate of greater than 98%. This is in 
contrast to patients with thicker lesions (> 4 mm) who have 5-year survival rate of 
less than 50%.  
  
4.2. Melanoma therapies 
4.2.1 Surgery 
  Complete surgical excision with adequate margins and assessment for the presence 
of detectable metastatic disease along with short- and long-term followup is a 
standard procedure.  
 
4.2.2. Chemotherapy  
   Various chemotherapeutic regimens have been tried without significantly 
increasing overall survival rates of metastatic melanoma patients (159). An increasing 
number of small molecules have been developed in the last years, which may be 
promising for melanoma therapy (160-162). They aimed to specifically target 
different specific features of melanoma cells like proliferation, metastasis, 
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angiogenesis and in particular apoptosis deficiency. MAPK and PI3K/AKT 
(phosphatidylinositol 3-kinase/protein kinase B) signalling pathways appear to be 
especially promising targets for the treatment of advanced melanoma (163). 
 
4.2.3. Radiotherapy 
  Melanoma has long been considered to be relatively radio-resistant and therefore the 
mainstay of treatment has been surgery. Although radiotherapy has a relatively low 
probability of achieving long-term control in patients with incompletely resectable 
locoregional disease, it has been increasingly employed postoperatively to improve 
locoregional control in patients at a high risk for residual subclinical disease after 
surgery (164). 
 
4.2.4. Immunotherapy  
  Immunotherapy has a long history in patients with melanoma, including a number 
of different strategies of vaccines utilizing whole tumor cells, peptides, DCs, DNA 
and RNA, and antibodies. To date, IL-2 and IFN-α2b are the only approved 
immunotherapeutic agents for melanoma. Studies have demonstrated that IL-2 
allowed a complete and long-lasting remission in this disease, although only in a 
small percentage of patients (165). For patients who are at a high risk of developing 
recurrent disease, the treatment with IFN-α2b in the adjuvant setting has been shown 
to improve the overall survival from 2.8 to 3.8 years (166).  
 
4.2.5. DC vaccination 
  Earlier small clinical trials using DCs showed promising results, with frequent 
induction of anti-cancer immune reactivity and clinical responses (167). In recent 
years, additional trials have been carried out in melanoma patients.  
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DC sources 
  The addition of DCs to the adjuvants for cancer immunotherapy has been possible 
due to the introduction of new methods of DC isolation and generation. A 
breakthrough was achieved after the discovery that DCs might be generated from 
peripheral monocytes or CD34+ bone marrow precursors in the presence of GM-CSF 
and IL-4 (168). The most commonly used factors for DC maturation are cytokine 
cocktails, including PGE2, IL-1β, IL-6 and TNF-α (169). PGE2 is believed to 
enhance the migratory/homing capacity of the DC (170) by upregulating the 
expression of chemokine receptor CCR7. However, PGE2 possibly also mediated TH2 
polarisation and secretion of the immunosuppressive cytokine IL-10 (171). 
Furthermore, Banerjee et al. (172) showed that cytokine production of DCs matured 
by these cytokine cocktail were more prone to expand immunosuppressive T 
regulatory cells than immature DCs.   
  An improved protocols for maturation of DC inducing of TNF, IL-1β, PolyI:C, 
IFN-α and IFN-γ (αDC) has been proposed (173). αDC cocktail-matured DC 
displayed superior immunogenic abilities compared to standard cocktail-matured DC 
and have retained lymph node migratory capacities in vitro even though PGE2 was 
not added. Nevertheless, the published advantages of αDC1 maturation were not 
reproducible when DCs were prepared in plasma containing medium (174).  
  As an alternative to the well-defined but expensive cytokine cocktails 
monocyte-derived conditioned medium has been used for DC maturation (175). 
Presumably, this supernatant from activated monocyte cultures contains critical 
maturation factors (176).  
 
Critical issues for optimal DC vaccination 
  Apart from choosing the right source of DCs and the right method of DC 
maturation, critical issues for successful vaccination involved the choice of antigen, 
the antigen loading, and the route of administration. 
  A wide range of antigenic preparations are available for loading of DC, including 
30 
Introduction 
including peptides, whole proteins, tumor lysate, or apoptotic tumor cells. DCs could 
be transfected with mRNA or cDNA encoding tumor antigens or fused with whole 
tumor cells (177). 
  After pulsing with the tumor antigen, DCs need to be administered to the cancer 
patients. Several possible injection modes were used, such as intravenous (i.v.), 
intradermal (i.d.), subcutaneous (s.c.), intralymphatical (i.l.) or intranodal (i.n.) 
injections. Morse et al. (178) showed that DC injected i.v. primarily accumulated in 
the lungs and subsequently redistributed to the liver, spleen and bone marrow, while 
DC migrated to the regional lymph nodes after i.d. or s.c. injection. In another study, it 
was demonstrated that i.d. and i.l. administration induced a T-cell IFN-γ response, 
whereas i.v. injection resulted in a humoral response (179), suggesting that the nature 
of the immune response varied with the route of injection. Intranodal injections have 
been previously claimed to be superior to i.v. or i.d. injection (180). However, Kyte et 
al. (181) found i.d. injection to be significantly better in the inducing immune 
responses compared to i.n. inoculation. Thus, the most favourable combination of DC 
maturation status and routes of injection still need to be clarified. 
 
IL-2 and helper antigen 
  IL-2 was frequently used as the DC vaccination adjuvant. It can potently stimulate 
T-cell growth and was administered in combination with DCs for enhancement of 
T-cell proliferation and differentiation into effector cells to improve vaccine efficacy 
(182). On the other hand, high dose IL-2 therapy has been found to promote 
expansion of regulatory T-cells and could thereby potentially limit antigen specific 
immune responses (183). Even low doses of IL-2 for a period of two weeks were able 
to expand CD4+CD25+ Tregs in cancer patients (184).  
  Helper antigens in the form of microbial components such as keyhole limpet 
haemocyanin (KLH), tetanus toxoid (TT) and hepatitis B virus antigen (HBsAg) were 
also added to the vaccine. These compounds interact with the Toll like receptors and 
promote cytokine secretion and inflammation. In addition, KLH amplified a TH1-type 
cellular tumour-specific response when added to the lysate, suggesting that helper 
T-cell epitopes contained within KLH may enhance the ability of DCs to induce CTL 
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responses (185).  
 
DC clinical trials 
  During the past decade a large number of DC vaccination studies have been 
performed (186). Although no significant correlation with objective response was 
found, clinical responses (complete response, CR; partial response, PR; stable disease, 
SD) significantly correlated with an induction of vaccine specific T cells as measured 
by ELISPOT (187). These findings are very encouraging for the ongoing work to 
optimize immune monitoring in clinical vaccination trials including defined standards 
for monitoring CD8+ T-cell response against the used tumor antigen during 
vaccination (188, 189). However, it is still questionable if these T cells are really able 
to kill their tumor target in vivo, since it was demonstrated that vaccine specific 
memory CD8+ T cells could secrete IFN-γ and proliferated also in patients without 
objective clinical responses (190)  
  A few trials showed correlation between survival and immunologic response. For 
example, Kyte et al. (181) showed that DC vaccinated patients survived longer than 
non-vaccinated when retrospectively compared to a control group of patients 
receiving standard treatment. In addition, subgroup analyses indicated that vaccination 
treated HLA-A2+/HLA-B44− patients survived longer than dacarbazine treated 
patients (191). Even though the data lack sufficient statistical strength, they emphasize 
the importance of careful patient selection for these kinds of trials.    
  Taken together, there is no doubt that DC vaccines can prime and boost 
antigen-specific T-cell responses in patients. Although definite advantages in using 
DC vaccines still could not be observed, it is believed that the full potential of these 
potent immunostimulatory cells has not yet been entirely exploited. Larger clinical 
trials comparing DCs with other vaccination strategies in patients with similar stages 
of disease and using standardized immunomonitoring protocols would be beneficial 
for tumor immunotherapy.    
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5. Ret transgenic spontaneous melanoma mouse model 
  In contrast to human situation with a strong association between UV exposure and 
melanoma development (192), normal adult mice do not develop melanomas, even 
after chronic exposure to UV radiation. Shaved or hairless mice have been exposed to 
various acute (intense, short-term) and chronic (low level, long-term) UV treatments 
to simulate human sun exposure. These treatments promote various types of skin 
cancers including squamous cell carcinoma, papilloma, and fibrosarcoma, but not 
melanoma (193). Even a combined treatment with carcinogens like 
7,12-dimethylbenz[a]anthracene (DMBA) promoted little or even no melanoma 
development, although there was a significant increase in the frequency of other skin 
cancers (194).  
The conventional animal melanoma models are based on the transplantation of 
tumor cells (e.g., B16), in which the natural history of the disease and tumor-host 
interactions are not comparable with the clinical situation. In contrast to 
transplantation models, a recently described ret transgenic mouse model closely 
resembles human melanoma with respect to tumor genetics, histopathology and 
clinical development (195). 
  Ret transgenic mouse model (C57BL/6 background) was described by Kato et al. in 
1998 (195). By introducing the recombinant human proto-oncogene ret fused to 
mouse metallothionein-I (MT) promoter-enhancer, primary melanoma in ret 
transgenic mice develops subcutaneously. Tumors at the late stage of development 
metastasize to the lymph nodes, lung, brain, kidney, liver and spleen (195), which 
corresponds well to that in human skin malignant melanomas, in which the lymph 
nodes and lung are the most common sites of distant metastasis (196)  
  The mechanism of melanoma development in ret transgenic mice is still under 
investigation. Kato et al. (195) reported that the level of Ret protein expression and 
activity at the benign stage was much higher than those in the skin with melanosis at 
the tumor-free stage. And the expression level and kinase activity of Ret in tumors at 
the malignant stage were further elevated, which lead to the activation of its 
downstream signaling molecules, such as Erk2 and c-Jun. Tumors at the malignant 
stage showed also a high activity of matrix metalloproteinase-9 (MMP-9) and MMP-2, 
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which are indicators of the potential capability for tumor invasion and metastasis 
(195). 
  Finally, Felbert et al. (197) showed that IL-6 gene ablation in ret transgenic mice 
could lead to a decrease of both melanoma incidence and tumor size. The mechanism 
of IL-6-induced tumor progression is probably due to constitutive activation of PI3K 
in tumors. 
 
6. Aims of the study 
  DC dysfunctions have been reported in many types of human tumors and tumor 
animal models. However, the mechanisms of the DC impairment during tumor 
progression are still not completely clear. The objective of this work was to 
investigate the mechanisms of the acquirement of tolerogenic properties by DCs in the 
process of melanoma development. Using ret transgenic mouse model of spontaneous 
melanoma, which closely resembles human melanoma as regard to tumor genetics, 
histopathology and clinical development, the following questions were addressed: 
1) whether DCs from ret transgenic tumor bearing mice display a tolerogenic 
pattern of phenotype and function during tumor progression; 
2) which tumor-derived cytokines and growth factors as well as transcription 
factors from their signaling pathways are involved in the driving of DCs to 
become tolerogenic; 
3) how to reconstitute the impaired function of DCs and to improve thereby 
anti-tumor immune responses in tumor bearing mice. 
  By addressing these questions, we hope to find a strategy which may benefit 
immunotherapy in melanoma patients. 
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II. Materials and methods 
 
7. Mice and cell lines 
  All mice were crossed and kept under specific pathogen-free conditions in the 
animal facility of German Cancer Research Center (Heidelberg). Experiments were 
performed in accordance with government and institute guidelines and regulations. 
 
7.1. Ret transgenic spontaneous melanoma mouse model 
  Ret transgenic mice (C57BL/6 background), which express human Ret 
proto-onkogene in melanocytes under the control of mouse metallothionein-I 
promoter-enhancer were kindly provided by Dr. I. Nakashima (Japan) (185). The 
survival and general performance of mice was monitored at least twice a week. 
Spontaneous tumor development was assessed macroscopically. 
 
7.2. OT-I transgenic mice 
  Homozygous OT-I mice, which express transgenic TCR (Vα2/Vβ5) specific for 
ovalbumin (OVA)-derived peptide SIINFEKL, were kindly provided by Dr. B. Arnold 
(Germany).  
 
7.3. Cell lines 
  Cells were all cultured in 5% CO2 at 37 °C. 
Ret melanoma cell line 
Ret melanoma cell line was established from the primary skin tumor of Ret 
transgenic mouse. Cells were cultured in RPMI-1640 medium supplemented with 
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10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, L-glutamin and 5 x 10-5 
mol/L 2-mercaptoethanol (2-ME). 
Ret melanoma cells (2 x 105 cells/ml) were cultured in complete medium for 48h. 
Supernatants were then collected and stored at -20 °C. 
B16F10 cell line 
  B16F10 melanoma cell line was cultured in DMEM medium supplemented with 
10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, and L-glutamin. 
 
8. Chemicals, buffers/medium, antibodies/cytokines 
8.1. Chemicals 
3-Amino-9-ethyl-carbazol (AEC) tablets     Sigma, Cat.#A6926 
Agarose                              Roth, Cat.#2267.2 
Ammonium chloride (NH4Cl)               Merck, Cat.#101141 
Bovine serum albumin (BSA)                 Sigma, Cat.#7030-50G 
Dimethylsulfoxid (DMSO)                    Merck, Cat.#109678 
GeneRuler™ 100bp DNA Ladder Plus           Fermentas, Cat.#SM0321 
EDTA disodium                        GERBU, Cat.#1034 
0,5M EDTA (pH 8.0)                         GIBCO, Cat. #15575-098 
100% Acetic acid (CH3COOH)                 Merck,  Cat.#100063 
1% Ethidium bromide                   Merck, Cat.#111608 
Fatal bovine serum (FBS) PAN Biotech GmbH,   
Cat.#3702-P260718 
30% Hydrogen peroxide (H2O2)                Sigma, Cat.#H1009 
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Isofluran                            DeltaSelect 
2-mercaptoethanol (2-ME)                     Merck, Cat.#444203 
Potassium hydrogen carbonate (KHCO3)          Roth, Cat. #P748 
Sodium acetate (CH3COONa)                  neoLab, Cat.#4720 
Sodium azide (NaN3)                         Roth, Cat.#K305 
Sodium carbonate (Na2CO3),                   AppliChem, Cat.#A3900 
Sodium chloride (NaCl)                       Fluka, Cat.#71379 
Sodium hydrogen carbonate (NaHCO3)          AppliChem, Cat.#A3084 
N,N – Dimethylformamid (DMF)               Sigma, Cat.#D-4551 
1x PBS                               PAA, Cat.#H15-002 
100x Penicillin / Streptomycin                  PAA, Cat.#P11-010 
Phenol / Chloroform                  Roth, Cat.#A156-1 
Potassium bicarbonate (KHCO3)                Sigma,  Cat.#P9144 
Sodium Dodecyl sulfate (SDS)                  Gerbu, Cat.#1212 
Proteinase K                            Sigma, Cat.#P6556 
Tris                                        Roth, Cat.#4855.1 
Trizol                             Invitrogen,  Cat.#15596-026 
0.4% Trypan blue solution              Sigma, Cat.#T8154 
Tween20                            Sigma, Cat.#P-2287 
Xylene                             J.T. Baker, Cat.#3410 
Goat serum                            GIBCO, Cat.#PCN5000 
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8.2. Buffers / medium 
Enzyme-linked immunosorbent assay (ELISA) 
Assay Diluent   
1x PBS containg 10% FBS (v/v) 
Wash buffer    
1x PBS containing 0.05% Tween20 (v/v) 
 
Enzyme-linked immunosorbent spot (ELISPOT) 
AEC buffer 
A tablet of AEC (20 mg) was dissolved into 2.5 ml dimethylformamide in a 50 ml 
Falcon tube. 8.4 ml 0.2 M sodium acetate, 3.5 ml 0.2 M acetate acid and 35.6 ml H2O 
were then added. After mixed well, solution was filtered with 0.45 μm filter and 25 μl 
H2O2 was added. The prepared AEC buffer should be kept in dark and used within one 
month after preparation.  
Coating buffer   
Buffer A: 1,59 g Na2CO3 dissolved in 100 ml H2O  
Buffer B: 2,93 g NaH2CO3 dissolved in 100 ml H2O 
Working coating buffer (pH 9.6) was prepared by adding 1 ml A, 1 ml B and 8 ml 
H2O into a 15 ml Falcon tube. 
Wash buffer 
1x PBS containing 0.05% Tween20 (v/v) 
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Flow cytometry (FACS) 
FACS 
1 x PBS containing 2% FBS and 0.2% NaN3 
FACS blood buffer 
1x PBS containing 2% FBS, 0.2% NaN3, and 0.02% Liquemin N 
Red blood cell lysis buffer   
8,29 g NH4Cl, 1 g KHCO3, and 37,2 mg EDTA were dissolved in 1 L H2O pH (7.2-7.4) 
as a 10-time stock solution. 1-time working buffer was prepared by diluting stock 
solution with H2O. 
 
Agarose gel electrophoresis 
DNA loading buffer 
6 x loading buffer (0.25% bromphenol blue and 30% glycerol) was diluted with H2O 
to make 1x loading buffer 
TAE-Puffer    
242 g Tris, 100 ml 0.5 M EDTA, and 57.1 ml pure acetic acid were mixed with H2O 
to reach a final volume of 1 liter. 
  
Immunhistochemistry 
Blocking buffer 
1x PBS containing 10% goat serum, 2% BSA and 0.05% Tween-20 
Antibody diluent 
1x PBS containing 2% goat serum, 2% BSA and 0.05% Tween-20 
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Wash buffer     
1x PBS containing 0.05% Tween-20 
 
Polymerase chain reaction (PCR) 
PCR Mix     
To prepare 50 μl PCR mix, 5 µl 10x Reaction Puffer, 1 µl 10 mM dNTPs, 2 µl of each 
primer stock, 0.5 µl Taq Polymerase, 3 µl templates and 37 µl ddH2O were mixed 
Digesting buffer 
50 mM Tris, 20 mM NaCl, 1 mM EDTA and 1% SDS in H2O 
 
Magnetic activated cell sorting (MACS) buffer 
PBS with 0.5% BSA and 2 mM EDTA 
 
8.3. Medium  
Complete culture medium 
  RPMI 1640 supplemented with 10% heat-inactivated FCS, 100 U/ml penicillin, 100 
mg/ml streptomycin, L-glutamin and 5 x 10-5 mol/L 2-mercaptoethanol (2-ME) was 
used for cell culture unless especially mentioned. 
DC medium      
RPMI 1640 supplemented with 10% heat-inactivated FCS, 100 U/ml penicillin, 100 
mg/ml streptomycin, L-glutamin, 5 x 10-5 mol/L 2-mercaptoethanol (2-ME), 10 ng/ml 
recombinant mouse GM-CSF, and 10 ng/ml recombinant mouse IL-4.  
10x Trypsin / EDTA   
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  10x Trypsin / EDTA was purchased from PAA (Cat.#L11-003) 
 
2.4. Antibodies 
  All antibodies for flow cytometry were purchased from BD Biosceiences: 
biotin-conjugated hamster anti-mouse CD11c (clone HL3); fluorescein isothiocyanate 
(FITC)-conjugated rat anti-mouse I-A/I-E (MHC class II, clone 2G9); 
R-phycoerythrin conjugated rat anti-mouse CD40 (clone 3/23), hamster anti-mouse 
CD80 (clone 16-10A1), rat anti-mouse CD86 (clone GL1); PerCP-Cy5.5 mouse 
anti-mouse CD45.2 (clone 104).  
  Rat monoclonal antibody against mouse interferon gamma (IFN-γ) (clone 
RMMG-1) was bought from Biosource. Stock concentration was 2.5 mg/ml. Aliquots 
were stored at -20 °C.  
  Rat anti-mouse IFN-γ (clone XMG1.2, BD Biosciences, Cat. #554410) was used as 
a detection antibody for ELISPOT. 
  Monoclonal antibody against IL-6 (Cat. #MAB406), TGF-β1 (Cat. #MAB240), and 
VEGF (Cat. #AF-493-NA) were purchased from R&D Systems.  
  Antibodies against phosphorylated p38 MAPK (Thr180/Tyr182) (Cat. #9215), 
phosphorylated STAT3 (Tyr705) (Cat. #9131), phosphorylated Smad3 (Ser423/425) 
(Cat. #9520), and phosphorylated Erk1/2 MAPK (Thr202/Tyr204) (Cat. #4377) were 
purchased from Cell Signaling Technology. 
 
2.5. Cytokines 
  Recombinant mouse granulocyte macrophage-colony stimulating factor (GM-CSF, 
eBiosciencee) was shipped as100 μg/ml stock and stored at -20 °C in 10 μl aliquots. 
  Recombinant mouse IL-4 (R&D systems) was reconstituted in sterile PBS 
containing 0.1% bovine serum albumin to reach a stock concentration of 100 μg/ml, 
and stored at -20 °C in 10 μl aliquots. 
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8.6. Other reagents  
  SIINFEKL peptide was synthesized in the core facility of German Cancer Research 
Center (Heidelberg).  
  Phosphothioate (PTO)-modified CpG ODN 1668 (5’-TCC ATG TTC CTG ATG 
CT-3’) and primer pairs for RT-PCR were obtained from MWG. 
  Lipopolysaccharide (LPS, Sigma-Aldrich, Cat. #L2654) was dissolved in PBS at a 
1mg/ml concentration and aliquots were stored at -20°C.  
  SB203580 (a specific p38 MAPK inhibitor, Sigma-Aldrich, Cat. #S8307) was 
dissolved in DMSO to make a 10 mM stock concentration and aliquots were stored at 
-20 °C. 
 
9. Reagent kits 
9.1 MACS kit 
  CD11c (N418) Microbeads (Cat. #130-052-001) and CD8a+ T-cell isolation kit (Cat. 
#130-090-859) were purchased from Miltenyi Biotec. 
 
9.2. ELISA kit 
  ELISA kits for mouse IL-12p70 (Cat. #555256), IL-10 (Cat. #555252), and IFN-γ 
(Cat. #555138) were BD OptEIATM Sets purchased from BD Biosciences. 
 
9.3. 3,3’,5,5’ tetramethylbenzidine (TMB) substrate reagent kit 
  TMB substrate reagent kit is used together with BD OptEIATM ELISA sets.  
Substrate Reagent A in the kit contains hydrogen peroxide, and Substrate Reagent B 
contains TMB. 
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9.4. Luminex cytokine assay  
  Kits for luminex cytokine assay include 23-plex Bio-Plex mouse cytokine (Bio-Rad, 
Cat. #171-F11241), single plex mouse cytokine for VEGF (Bio-Rad, Cat. 
#XD0000007B), M-CSF (Bio-Rad, Cat. #XD0000000G), and TGF-β1 (Millipore, Cat. 
#TGFB-64K-01). 
 
9.5. Immunhistochemistry 
Vectastain ABC-AP Kit                   Vector Laboratories, Cat.#AK-5000 
Alkaline Phosphatase Substrate Kit          Vector Laboratories, Cat.#SK-5100 
 
10. Routine laboratory materials  
10.1. Devices  
ELISA Reader             Rainbow Thermo (SLT) 
ELISPOT Reader         Bioreader 3000 (Biosys)  
FACS machine          FACSCalibur 4-Farben (BD) 
        FACSLSRII 6-Farben (BD) 
Fume hood         STA 120 1297 (Prutscher)  
Refrigerator (-80 °C)    HeraFreeze (Heraeus) 
Gel chamber           40-1214 (PeqLab) 
Gel chamber power supply unit   EC105 (Apparatus Corporation) 
Gel photo chamber        Gel Jet Imager INTAS (UV Systems) 
Warming block         Thermomixer compact (Eppendorf) 
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Incubator              HeraCell (Heraeus) 
Refrigerator (-20 °C)           Premium (LiebHerr) 
Microscopes              DMIL (Leica) 
                     DMRE (Leica) 
Microscope camera         DC500 (Leica) 
Microtome              RM 2125 RT (Leica) 
Microtome water bath      HI 1210 (Leica)  
Microwave oven        R-352 (Sharp) 
PCR-System             DNA-Engine DYAD (MJ Research) 
pH meter               766 (Calimatic) 
Photometer              UltroSpec 3100pro (Amersham) 
Laminar flow                Hera Safe (Thermo Electron Cooperation) 
Container for liquid nitrogen    Isotherm (KGW) 
Liquid nitrogen tank       Biosafe MD (Messer) 
Timer                 Oregon Scientific 
Vortex                 REAX top (Heidolph) 
                   Vortex Genie 2 (Scientific Industries) 
Weighing machine    BP 3100P (Sartorius) 
Water bath              DC3 (HAAKE / GFL) 
Centrifugers                Labofuge 400R (Heraeus) 
                   Biofuge pico (Heraeus) 
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                  Biofuge primo R (Heraeus) 
                  Varifuge K (Heraeus) 
                  RT 7 Plus (Thermo Electron Cooperation 
  
10.2. Routine laboratory materials 
ELISA Plates          MaxiSorp 96-well, Nunc, Cat.#442404 
ELISPOT Plates Silent Screen Plate 96-well clear w/o Lid,, Nunc,     
Cat.#256154  
Needles               0,4x19 mm Mikrolance (BD) 
                  0,3x13 mm Mikrolance (BD) 
Cryo tubes             Cryo.s (Greiner) 
Pipets witht adjustable volumes 
                     2-20 µl, 20-200 µl, 200-1000 µl; Rainin 
Objekt carrier          76x26 mm SuperFrostPlus 
                  (Menzel-Gläser) Cat. J1800AMNZ 
Coverglass                   24 x 24 mm  (Roth) 
Tubes 15 ml / 50 ml           Polypropylen (Falcon)      
0.5 ml Eppendorf tubes 
1.5 ml Eppendorf tubes 
2 ml Eppendorf tubes 
Syringes                 1 ml Plastipak (BD) 
                  5 ml (Terumo) 
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                  50 ml (Terumo) 
Cell culture plates         96-well-Platte (Greiner) 
                  24-well-Platte (TPP) 
                  6-well-Platte (Greiner) 
Cell strainer            100µm; Nylon (BD Falcon) 
   
11. Softwares for data analysis 
  Flowjo (Version 7.2.4), Tree Star, Inc., Ashland, USA 
  GraphPad PRISM (Version 4), GraphPad Software, Inc., San Diego, USA 
 
12. Methods 
12.1. Genotypization of ret transgenic mice 
  Each tail biopsy of ret transgenic mouse was digested in 20 µl Proteinase K 
digestion buffer at 56 °C for 3 h. Afterwards 300 µl ddH2O was added and tubes 
containing digested biopsies were put at 99 °C for 3 min to inactivate the enzyme 
activity. 3 µl freshly isolated DNA was added into 47 µl PCR Mix buffer and then 
PCR was performed. The PCR program was set as following: 
 - Step 1:  95 °C 5 min 
 - Step 2:    94 °C 1 min 
 - Step 3:    58 °C 1 min 
 - Step 4:    72 °C 1.5 min 
 - Step 5:    back to Step 1 for another 34 cycles 
 - Step 6:    72 °C  10 min 
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 - Step 7:  4 °C  for ever 
The primer sequences used for detecting ret gene expression in PCR mix were 
5’-AAA ATG CAG TCA GAT ATG GA-3’, 5’-ACT CGG GGA GGG GTT C-3’. 
β-actin is used as house keeping gene to qualify PCR process. The sequences for 
β-actin primers are 5’-CAC CGG AGA ATG GGA AGC CGA A-3’, 5’-TCC ACA 
CAG ATG GAG CGT CCA G-3’. 
Results for PCR were tested by 1.5% agarose gel electrophoresis. The gel was 
prepared by dissolving 1.5% agarose in 100 ml TAE buffer in microwave oven and 4 
µl ethidiumbromid was added to the heated agarose containing TAE buffer before 
watering the buffer to gel chamber. 
10 µl PCR product from each sample was loaded to prepared gel after mixed with 3 
µl 6x loading buffer and DNA marker was used to locate ret and β-actin genes. 
Potential of power adaptor is set at 100 V. PCR results were then photographed by gel 
photo chamber. 
 
12.2. Preparation of single cell suspension from mouse organs 
  Mice were killed by cervical dislocation after anestesy with isofluran.   
 
12.2.1 Spleen 
  Single cell suspension from mouse spleen was prepared using 9 cm petri dishes 
with 8-10 ml cold PBS. Spleens were damaged by a 5 ml syringe plunger and filtered 
through cell strainer (100 µm). Cells were washed once with cold PBS at 400 g for 5 
min. Red blood cells were lyzed with 1ml lysis buffer at room temperature for 3 min 
followed by adding 9 ml PBS to stop the reaction. After centrifugation (400 g, 5 min), 
cell pellets were resuspended in appropriate buffers to perform different assays. 
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12.2.2 Lymph nodes 
Freshly isolated mouse lymph nodes were smashed between two object carriers. 
The object carriers were then washed with cold PBS to completely remove the 
remaining cells. Cells were then washed once with cold PBS at 400 g for 5 min and 
resuspended in FACS buffer for the following flow cytometry. 
 
12.2.3 Bone marrow 
Bone marrow cells were obtained from femurs and tibiae and lyzed with 1 ml lysis 
buffer after centrifugation. Then 9 ml PBS was added to stop the reaction. After 
centrifugation (400 g, 5 min), cell pellet was resuspended in appropriate buffers to 
perform different assays. 
 
12.2.4 Tumor 
  Freshly removed tumor mass was pressed by a 5 ml syringe plunger through a 
cell strainer into a 50 ml Falcon tube. Cells were washed with cold PBS at 400 g for 5 
min. Cell pellet was resuspended in appropriate buffers to perform different assays. 
 
12.3. Flow cytometry 
  For phenotype analysis of DCs in lymphoid organs and primary tumors, single cell 
suspensions were treated with Fc-block solution followed by incubation with mAbs 
against MHC classII-FITC, biotinylated CD11c, CD40-PE, CD80-PE, and CD86-PE 
for 20 min at 4 °C. After washing with FACS buffer, cells were treated with 
streptavidin-APC for 10 min at 4 °C. If measurements need to be performed on other 
day, cells were fixed in 2% paraformaldehyde (PFA) until measurement. Before 
measured in flow cytometer, cells were washed and resuspended in PBS. 
  To test phosphorylation levels of p38, Erk1/2, STAT3, and Smad3 ex vivo, freshly 
isolated splenocytes were fixed in 2% PFA for 10 min at 37 °C and permeabilized in 
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100% methanol for 30 min on ice followed by extensive washing with PBS. Purified 
rabbit anti-mouse antibody against p38, Erk1/2, Stat3, or Smad3 were added to the 
cell suspension together with biotinylated CD11c mAbs for 1 h at room temperature. 
After being washed, cells were incubated with goat anti-rabbit antibodies labeled with 
Alexa Fluor 488 and streptavidin-APC antibodies for 30 min at room temperature. 
Afterwards, cells were washed and measured in flow cytometer. 
  Acquisition was performed by four-color flow cytometry using a FACSCalibur with 
CELL-Quest software (BD Biosciences) or FACSCantoII with Diva software. Dead 
cells were excluded based on scatter profile or propidium iodide inclusion. FlowJo 
software (Tree Star) was used to analyze at least 100,000 events. Data were expressed 
as dot plots or histograms. 
 
12.4. Bone marrow-derived DC culture 
  Bone marrow cells were cultured in complete culture medium supplemented with 
10 ng/ml GM-CSF and 10 ng/ml IL-4 in 9 cm petri dishes (2 x 106 cells in 10 ml 
medium). On day 3, another 10 ml fresh medium was added. On day 6 and 8, 10 ml of 
supernatant from each plate was collected and centrifuged followed by resuspending 
cell pellet with 10 ml fresh medium. Cells were ready to be used as immature DCs at 
day 8-10.  
 
12.5. Isolation of DCs from spleen  
  DCs were isolated from spleens using CD11c magnetic beads according to 
manufacturer’s instroction. Cells were centrifuged at 400 g for 5min, resuspended in 1 
ml ice cold sterile PBS containing 2% FCS, 25 μl 40 mg/ml collagenase IV, 250 μl 20 
mg/ml DNAse and incubated for 25 min at room temperature. Then, 5 ml PBS 
containing 2% FCS was added to stop the reaction. Cells were then passed through 
cell strainer and carefully overlayed on 3 ml Lymphoprep solution in a 15 ml tube. 
After 30 min centrifugation (400 g, no shake), supernatant from upper phase and 
interphase was transfered into a 15 ml tube and centrifuged at 300 g for 8 min at 4°C. 
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Cell pellets were resuspended in 400 μl MACS buffer and 100 μl CD11c Microbeads 
and incubated for 15 min at 4℃. After washing with 2 ml MACS buffer (400 g, 8 min, 
4°C), cells were resuspended in 500 μl MACS buffer and put onto pre-washed 
mini-columns. After the unlabeled cells flew through, columns were washed three 
times to completely remove unbounded cells. The magenetically labeled cells were 
flushed out by firmly applying the plunger supplied with the column. After 
centrifugation (400 g, 8 min, 4°C), cells were resuspended in the complete culture 
medium. 
 
12.6. DC cytokine secretion 
  For investigating cytokine secretion by bone marrow derived DCs, cells (5 x 105 
cells/ml) were stimulated with 1 μg/ml LPS for 24 h at 37 °C.   
  To study cytokine secretion by freshly isolated spleen DCs, cells (5 x 105 cells/ml) 
were stimulated with 3 μg/ml CpG 1668 for 24 h at 37 °C.  
  Supernatants were collected and stored at -20 °C in aliquots. IL-12p70 and IL-10 
levels in supernatants were tested by ELISA kit. 
 
12.7. T-cell priming and restimulation 
  Ex vivo isolated spleen DCs were loaded with SIINFEKL (100 ng/ml) for 1h at 
37°C, then washed and co-cultured with T cells (T cell/DC ratio = 10:1). In some 
experiments, DCs were co-incubated with naive CD8+ T cells isolated from spleens of 
OT-1 mice (1 x 105 T cells/well) for 3-4 days. In another set of experiments, DCs 
were co-cultured with OVA-specific CD8+ T cells for 40 h.  
  To test effect of SB203580, a p38 MAPK inhibitor, on the DC capacity to activate 
T cells, spleen DCs isolated using CD11c+ magnetic beads were loaded with 
SIINFEKL (100 ng/ml) with or without 10 μM SB203580 for 1 h at 37 °C. Then cells 
were washed for 3 times with complete culture medium to remove extra peptide. 
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Isolated CD8+ T cells from spleen of OT-I mouse (1x105 cells in 200 μl medium) were 
cocultured with peptide-loaded DCs at 1:5 ratio in U-bottom 96-well plate for 3 days 
at 37 °C. Supernatants were collected and stored at -20 °C in aliquots. IFN-γ level in 
supernatant was detected by ELISA kit. 
 
12.8. ELISA 
Mouse IL-12p70, IL-10, and IFN-γ ELISA assays were performed according to 
manufacturer’s instructions. ELISA plates were precoated with capture antibodies 
overnight at 4 °C, washed 3 times with the washing buffer (PBS with 0.05% 
Tween-20) and blocked with assay diluent (PBS with 10% FCS) at room temperature 
for 1 h. After next washing, standard and samples were incubated at room temperature 
for 2 h followed by 5 times washing with the wash buffer. Afterwards, detection 
antibodies and streptavidin-HRP reagent were added to each well, and incubated at 
room temperature for 1 h followed by 7 times washing with wash buffer. Then 
substrate solution was added to each well, and plates were incubated in dark around 
10-30 min. To stop the reaction, a stop solution (1 M H3PO4) was added to each well. 
Extension was measured using spectrophotometer at 450 nm. 
 
12.9. IFN-γ ELISPOT 
ELISPOT assays employ the sandwich ELISA technique. Either monoclonal or 
polyclonal antibodies specific for the particular cytokine was pre-coated onto a 
polyvinylidene difluoride (PVDF)-backed microplate. Appropriately stimulated cells 
were pipetted into the wells and the microplate was placed into a humidified 37 °C 
CO2 incubator for a certain period of time. During this incubation period, the 
immobilized antibody binds secreted cytokines in the immediate vicinity of the 
secreting cells. After washing away cells and unbound substances, biotinylated 
polyclonal antibodies specific for the chosen cytokine was added to the wells. After 
washing, alkaline-phosphatase conjugated to streptavidin was added. Unbound 
enzyme was subsequently removed by washing, and a substrate solution (AEC) was 
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added. A red colored precipitate forms and appears as spots at the sites of cytokine 
localization, with each individual spot representing an individual analyte-secreting 
cell. The spots can be counted with an automated ELISPOT reader system. 
In the present work, IFN-γ ELISPOT assay was performed as following. First, 
ELISPOT plates were coated with 50 μl diluted anti-IFN-γ antibody (10 μg/ml) 
overnight at 4 °C. After 5 times washing with sterile PBS, plates were blocked with 
complete culture medium (200 μl/well) at 37 °C for 1 h. Then, block medium was 
removed and 100 μl cell suspension containing 1 x 105 naive OT-I CD8 T cells or 
1x104 OVA-specific T-cell line was pipetted to each well followed by adding peptide 
loaded DCs in 1:5 or 1:10 DC/T ratio. Cells were cultured for another 3-4 days (naive 
OT-I T cells) or 40 h (OVA-specific CD8+ T cell line esatablished upon peptide 
immunization of C57BL/6 mice via SIINFEKL together with T-helper peptide 
(aa128-140) derived from HBV core antigen). After co-culture, supernatants were 
removed and plates were washed 3 times with the wash buffer (PBS with 0.05% 
Tween-20). 50 μl biotinjulated anti-mouse IFN-γ antibody was added to each well and 
plates were incubated at room temperature for 2 h followed by 3 times washing with 
wash buffer. Then, 50 μl 1:100 diluted streptavidin-horseradish peroxidase was added 
to each well and plates were incubated at room temperature for 2 h followed by 3 
times washing with wash buffer and another 3 times washing with PBS. 100 μl AEC 
buffer was added to each well. Plates were incubated in dark for 5-20 minutes until 
clear red spots can be seen. To stop the reaction, plates were washed with tap water. 
After air dried, plates were read in Bioreader 3000. Spots measured in the presence of 
unpulsed DCs were considered as non-specific background (negative control). 
Samples were considered to contain OVA-reactive T cells producing IFN-γ when spot 
numbers in experimental triplicates were significantly higher than the numbers in 
negative control triplicates (p < 0.05). 
 
12.10. Reverse transcription (RT)-PCR 
RT-PCR is a process of converting RNA to DNA followed by PCR amplification of 
the reversely-transcribed DNA. First, complementary DNA (cDNA) is made from an 
mRNA template using dNTPs and reverse transcriptase. After the reverse transcriptase 
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reaction is complete, cDNA has been generated from the original single strand mRNA 
and standard PCR is initiated.  
In the current work, total RNA from investigated cells (freshly isolated spleen DCs, 
bone marrow derived DCs, and tumor cell lines) was extracted by using TRIZOL 
reagent according to the manufacturer’s instruction. RNA was reverse-transcribed to 
cDNA using Moloney murine leukaemia virus reverse transcriptase and random 
hexamers for 2 h at 42 °C. 3 μl cDNA was then amplified with 2.5 U of Tag 
polymerase in PCR reaction buffer using specific primer pairs. PCRs for β-actin were 
run to normalize the levels of mRNA in the samples. Primers used were: IL-10, 
5’-TCA AAC AAA GGA CCA GCT GGA CAA CAT ACT G-3’, 5’-CTG TCT AGG 
TCC TGG AGT CCA GCA GAC TCA-3’; TGF-β1, 5’-CTC CCA CTC CCG TGG 
CTT CTA G-3’, 5’-GTT CCA CAT GTT GCT CCA CAC TTG-3’; TLR4, 5’-AGT 
GGG TCA AGG AAC AGA AGC A-3’, 5’-CTT TAC CAG CTC ATT TCT CAC C-3’; 
IL-6, 5’-CCC AAC AGA CCT GTC TAT ACC-3’, 5’-CAG CTT ATC TGT TAG GAG 
AGC-3’; VEGF, 5’-TTA CTG CTG TAT CTC CAC C-3’, 5’-ACA GGA CGG CTT 
GAA GAT G-3’; β-actin, 5’-CAC CGG AGA ATG GGA AGC CGA A-3’, 5’-TCC 
ACA CAG ATG GAG CGT CCA G-3’.
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III. Results 
13. Genotypization and tumor development of ret transgenic mice  
  As shown in Fig. 13.1, the sample from mouse, which expressesed ret gene showed 
a clear band around 600kb (line S2), whereas the sample from non-transgenic 
littermate showed no band at this position (line S1).  
 
 
Figure 13.1. A typical genotypization result 
after agarose gel electrophoresis. Lines from 
left to right: DNA marker (Marker), positive 
control (p.c., cDNA from ret transgenic 
mouse), negative control (n. c., PCR product 
without adding cDNA template), sample 1 (S1), 
sample 2 (S2). 
   
After genotypization, tumor development of ret transgenic mice was monitored 
macroscopically twice a week. After a short latency (20-70 days of age), around 25% 
of all transgenic mice develop skin tumors subcutaneously on the face (nose, ears, 
eyes and neck), back or on the tail (Fig.13.2 A, B). Tumor bearing mice developed 
metastases in the lymph nodes (Fig. 13.2 C), lungs, liver and brain (data not shown).  
 
Tumor 
 
 
Figure 13.2. Melanoma development in ret 
transgenic mice. (A) Tumor localization in ret 
transgenic mouse (ret tu, right) is indicated with 
arrows. (B) Hematoxilin and eosin staining of 
the subcutaneous primary tumor. Magnification 
x 200. (C) Metastatic lymph nodes in ret 
transgenic mouse with macroscopical tumors. 
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14. Phenotype analysis of dendritic cells in lymphoid organs of ret 
transgenic mice 
  Phenotype of DCs from the spleen, bone marrow and lymph nodes of ret transgenic 
mice were analyzed using flow cytometry. MHC class II+ CD11c+ cells from above 
mentioned organs were considered as DCs. Expression of CD40, CD80 and CD86 
costimulatory molecules were used to investigate DC maturation status.  
 
14.1. Analysis of total DC numbers 
  Gating strategy used for the DC analysis is shown in Fig. 14.1 A. A significant 
reduction of DC number was found in both spleen and bone marrow (BM) of ret 
transgenic mice with macroscopical tumors (tumor bearing mice) as compared to 
non-transgenic littermates (wild type) or ret transgenic mice without macroscopical 
tumors (tumor free mice) (Fig. 14.1 B).  
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Figure 14.1. Analysis of DCs in the lymphoid organs of ret transgenic mice. Cells from ret 
transgenic mice with macroscopical tumors (ret tu) or without them (ret) as well as from 
non-transgenic littermates (WT) were stained with mAbs for CD11c, MHC class II, and 
leukocyte marker CD45.2 followed by flow cytometry. (A) Dot plots are representative of 
tumor bearing mice. CD11c+ MHC class II+ cells are defined as DCs. (B) Accumulative data 
for DCs in spleens and BM are expressed as the percentage within leukocytes. (C) 
Accumulative data for DCs in lymph nodes with macroscopic metastases (ret tu met) and 
without visible metastatic lesions (ret tu non-met) expressed as the percentage within 
leukocytes. Data are means ± SEM from 5-20 mice. * P < 0.05, significant differences 
between groups indicated with the lines.   
   
Similar to the spleen and BM, there was a significant decrease in total DC numbers 
in lymph nodes with metastasis (ret tu met) as compared to lymph nodes without 
visible metastases from the same tumor bearing mice (ret tu non-met), lymph nodes 
from tumor free or from wild type mice (Fig. 14.1 C). 
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14.2. Analysis of DC maturation status in spleen, BM and lymph nodes of 
ret transgenic mice 
  Next, we investigated the numbers of mature DCs in the spleen, BM and lymph 
nodes. A profound reduction in numbers of DCs expressing CD40, CD80 or CD86 
molecule was observed in all investigated lymphoid organs as compared to control 
groups (P < 0.05, Fig. 14.2 A-C).  
Figure 14.2. Decreased levels of mature DCs in 
lymphoid organs of ret transgenic tumor bearing 
mice. Cells from tumor bearing (ret tu), tumor 
free (ret) and wild type (WT) mice were analyzed 
by flow cytometry using mAbs for CD11c, MHC 
class II, CD45.2 and costimulatory molecules 
CD40, CD80 and CD86. Results (means ± SEM) 
from 4-16 animals are expressed as the 
percentage of CD40+, CD80+ or CD86+ DCs 
among CD45.2+ leukocytes. * P < 0.05, 
differences between indicated groups. 
 
These data indicated a systemic decrease in numbers of total and mature DCs in 
lymphatic organs from ret transgenic mice with macroscopical tumors. No statistical 
correlation between observed alterations and mouse age, tumor weight or the 
dynamics of tumor growth was found (data not shown). 
 
15. Phenotype analysis of tumor infiltrating DCs  
  Furthermore, phenotype of tumor infiltrating dendritic cells (TIDCs) was 
investigated in primary tumors. There are two ways to get a single cell suspension of 
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tumor tissue: 1) to destroy tumor tissue mechanically; 2) to digest tissue with enzymes, 
such as collagenase and DNase. In our experiments, single cell suspension from tumor 
samples was prepared mechanically to exclude the possibility to damage the 
expression of surface markers by the enzyme treatment. TIDC numbers were 
examined within alive CD45.2+ cells. CD45.2+ was used as a marker of tumor 
infiltrating leukocytes (TILs, Fig. 15 A). Tumor progression in ret transgenic mice 
with macroscopical tumors was evaluated by the tumor weight measurement after 
mice have been sacrificed. 
 
Figure 15. Tumor infiltration with DCs is dependent on tumor progression. Single cell 
suspensions prepared from tumors of ret transgenic mice were stained with mAbs for CD11c, 
MHC class II, CD45.2, and CD40. (A) Representative dot plots are shown. (B and C) The 
weight of each tumor sample are plotted against the percentage of tumor infiltrating DCs 
(TIDCs) within CD45.2+ tumor infiltrating leukocytes (TILs) (B) or against the percentage of 
CD40+ mature DCs within TIDCs (C). The correlation between the two variables was 
calculated using a linear regression analysis. 
 
  Elevating proportions of TIDCs among TILs were found to correlate with 
increasing weight of primary melanomas (r2=0.18; P <0.05; Fig. 15 B). Although 
more DCs infiltrated into larger tumors, obviously they did not correlate with a better 
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prognosis in ret transgenic mice. Therefore, we further investigated the relationship 
between the maturation status of TIDCs and tumor progression. Notably, in larger 
tumors, significantly higher amounts of TIDCs displayed immature phenotype 
according to the CD40 expression profile as compared to DCs infiltrating smaller 
tumors (r2=0.31; P <0.05; Fig. 15 C).  
This data implied that tumor attracted DC but blocked DC maturation at a more 
immature stage. The outcome of such effect was an accumulation of immature DCs in 
tumors leading thereby to the failure in the initiation of effective anti-tumor T-cell 
responses. 
 
16. Functional assay of dendritic cells of ret transgenic mice 
  To determine if DCs in ret transgenic mice with macroscopical tumors showed the 
functional impairment, spleen DCs were investigated for their cytokine production 
and the capacity to activate T cells. 
16.1. Cytokine profile of DCs 
  First, cytokine profile of DCs was tested at the mRNA level. Spleen DCs were 
isolated using CD11c+ magnetic positive selection kit and mRNA was extracted 
immediately after cell sorting. Expressions of TGF-β1 and IL-10 mRNAs in spleen 
DCs were shown in Fig. 16.1 A. Compared to ret transgenic mice without 
macroscopical tumors or non-transgenic littermates, DCs from ret transgenic mice 
with macroscopical tumors showed a tendency to express higher levels of TGF-β1 and 
IL-10 mRNAs.  
Next, we analyzed the cytokine production profile of DCs at the protein level. Two 
cytokines were investigated in these experiments: the pro-inflammatory cytokine 
IL-12p70 and the anti-inflammatory cytokine IL-10. However, due to very low 
production of cytokines in the steady state ex vivo, we did not detect IL-12 or IL-10 
producing DCs in the spleen, BM or lymph nodes by intracellular FACS staining (data 
not shown). Therefore, ex vivo isolated spleen DCs were stimulated with CpG 1668 (a 
TLR9 ligand) for 24 h. Supernatants were then collected and the production of 
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IL-12p70 and IL-10 was detected by ELISA in supernatants. DCs from ret transgenic 
mice with macroscopical tumors secreted significantly less IL-12p70 than DCs from 
mice of both control groups (P < 0.05; Fig. 16.1 B). Moreover, the amount of IL-10 
produced by tumor DCs was significantly increased as compared to DCs from 
non-transgenic littermates (P < 0.05; Fig. 16.1 C). In addition, the ratio between 
IL-12p70 and IL-10 produced by DCs from tumor bearing animals was found to be 
higher than by DCs isolated from wild type mice (P < 0.05; Fig. 16.1 D). 
 
Figure 16.1. DCs from tumor bearing mice (ret tu) display tolerogenic pattern of cytokine 
production as compared to tumor free (ret), and non-transgenic mice (WT). (A) TGF-β1 and 
IL-10 mRNA in freshly isolated spleen DCs was tested by RT-PCR. Results are representative 
of two independent experiments. Spleen DCs were stimulated with CpG1668 for 24h ex vivo 
followed by detection of IL-12p70 (B) and IL-10 (C) in supernatants using ELISA as well as 
calculation of IL-12p70/IL-10 ratio (D). Data are mean ± SEM from 10 mice per 
experimental group. 
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16.2. T cell stimulation capacity of DCs 
  To address the question whether the T cell stimulating capacity of DCs from ret 
transgenic mice with macroscopical tumors was also impaired, ex vivo isolated spleen 
DCs were loaded with ovalbumin (OVA) derived peptide, SIINFEKL, and cocultured 
with naive CD8+ T cells isolated from spleen of OT-I mice. These T cells can be 
specifically activated by SIINFEKL. After 3 days of co-culture, numbers of IFN-γ 
producing cells in ELISPOT assay were measured to evaluate capacity of DCs for T 
cell activation. As shown in Fig. 16.2 A, we detected significantly lower amounts of 
IFN-γ producing T cells in the presence of DCs from transgenic mice with 
macroscopical tumors than in samples with DCs from wild type mice (P < 0.05). 
  T-cell stimulation capacity of DCs from ret transgenic mice with macroscopical 
tumors was also investigated using an OVA-specific CD8+ T-cell line, which is 
established from OVA-immunized C57BL/6 mice. Data in Fig. 16.2 B indicated that 
DCs from tumor bearing mice are less potent for T cell stimulation when compared to 
tumor free or non-transgenic littermates.  
 
Figure 16.2. DCs from tumor bearing mice fail to promote a strong T cell stimulation. CD11c+ 
DCs were isolated using positive selection, loaded with the peptide SIINFEKL at 37oC for 1h 
and co-cultured for 3 days with CD8+ T cells isolated from spleens of OT-I mice (A), or 
co-cultured with an OVA-specific T cell line for 40h (B). T cell activation was evaluated by 
spot numbers in the IFN-γ ELISPOT assay. Means ± SEM from 4 animals per experimental 
group are shown. * P < 0.05, differences between indicated groups. 
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Taken together, the data on phenotype analysis showed that tumor bearing mice 
contained reduced numbers of total DCs as well as mature DCs in the lymphoid 
organs. Accumulation of immature DCs was found in the tumors, suggesting that in 
the process of tumor progression the suppressive tumor microenvironment blocked 
DC development at the immature stage. Moreover, DCs from tumor bearing mice 
showed their functional impairment. Such DCs secreted a less IL-12 and more IL-10 
after stimulation, and were less potent to activate T cells, suggesting that DCs from ret 
transgenic mice with macroscopical tumors displayed a tolerogenic pattern. 
 
17. Mechanisms of tolerogenic DC generation in ret transgenic mice 
  DCs from ret transgenic mice with macroscopical tumors were shown to display a 
tolerogenic pattern. It has been previously reported that tumor cells or tumor-derived 
factors could induce dysfunctional DCs in both carcinoma patients and tumor animal 
models (68, 70, 80, 88, 97).  
Therefore, we aimed to further study 1) at which level of DC differention can 
tumor-derived factors influence DC function, 2) which tumor-derived factors may be 
particularly important in tolerogenic DC generation during melanoma progression in 
ret transgenic mouse model, and 3) which transcription factors could play a crucial 
role in the turning of DCs to acquire tolerogenic functions during melanoma 
progression in ret transgenic mouse model. 
17.1. Generation of tolerogenic DCs from BM precursors of ret transgenic 
mice in vitro 
DCs were generated from precursor cells derived from the BM of ret transgenic 
mice with macroscopical tumors in the presence of recombinant mouse IL-4 and 
GM-CSF in vitro. As shown in Fig. 17.1.1, DCs generated from precursor cells 
derived from ret transgenic mice with macroscopical tumors showed significantly 
lower expression of MHC class II molecule as compared to non-transgenic littermates, 
although the total number of generated CD11c+ cells was not changed. This indicated 
that the tumor microenvironment in vivo changed the ability of precursor cells to 
differentiate into mature DCs. 
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sample 
 
Figure 17.1.1. Phenotype analysis of DCs generated from precursors derived from bone 
marrow of ret transgenic mice with macroscopical tumors (ret tu). Immature DCs were 
stimulated 1μg/ml LPS for maturation. After 24h, phenotypes of mature DCs were tested by 
antibodies against MHC classII, CD40, CD80, and CD86. CD11c is used as DC marker. Data 
are representative for five experiments.  
 
Furthermore, we observed a stronger expression of IL-10 and TGF-β1 mRNA after 
LPS stimulation in DCs generated from BM precursors from ret transgenic mice with 
macroscopical tumors than from non-transgenic littermates. This may not be due to 
the different expression level of LPS receptor, TLR4, on DCs, because the expression 
of TLR4 mRNA was found to be comparable between the groups (Fig. 17.1.2A). 
Testing cytokine secretion by in vitro generated DCs after stimulated with LPS, we 
also revealed a significant decreased IL-12p70 production by DCs from tumor bearing 
group as compared to wild type group (P < 0.05; Fig. 17.1.2 B). In this experimental 
setting, IL-10 production in supernatant was under the detection level (data not 
shown).  
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Figure 17.1.2. The profile of cytokine and growth factor expression in DCs generated from 
bone marrow precursors of ret transgenic mice with macroscopical tumors (ret tu). Generated 
DCs were stimulated 1 μg/ml LPS for 24h. (A) mRNA was extracted from DCs and 
expression of IL-10 and TGF-β1 were examined by RT-PCR. Data are representative for five 
experiments. (B) Supernatants were collected and IL-12p70 expression level was tested by 
ELISA. Data are expressed as means ± SEM from four experiments (*, P <0.05).  
 
  Our data indicated that tumors suppressed the ability of BM precursor cells to 
differentiate into mature DCs, which led to the generation of DCs with more 
immature phenotype and suppressed IL-12 production in vitro. 
 
17.2. Production of immunosuppressive cytokines and growth factors in tumor 
bearing mice in vivo and by Ret melanoma cells in vitro 
To investigate which tumor-derived factors could be involved in the development 
of DCs with a tolerogenic profile, we first examined the expression of some cytokines 
and growth factors like IL-6, IL-10, VEGF, and TGF-β1 by RT-PCR at the mRNA 
level in the melanoma cell line, which was established from primary skin melanomas 
in ret transgenic mice (Ret melanoma cells), and in B16F10 melanoma cells used as a 
control. As shown in Fig. 17.2 A, IL-6, VEGF and TGF-β1 mRNAs were detected in 
both cell lines, whereas the IL-10 mRNA expression was not detectable (data not 
shown). Considerable amounts of VEGF and TGF-β1 proteins were demonstrated in 
supernatants from cultured Ret melanoma cells by the single-plex technology (data 
not shown).  
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Next we analyzed the expression of all four above mentioned factors in primary 
tumors freshly isolated from ret transgenic mice both at mRNA and protein levels. 
Similar to above mentioned cell lines, primary cutaneous melanomas expressed IL-6, 
VEGF, and TGF-β1 mRNAs; however IL-10 mRNA was not found (Fig. 17.2 A). At 
the protein level, we observed IL-6, VEGF and TGF-β1 production in primary tumors 
using multiplex and single-plex technology. Notably, level of VEGF in primary 
tumors were found to correlate with the tumor weight (r2=0.54; P <0.05; Fig. 17.2 B). 
Moreover, concentrations of IL-6 and VEGF were significantly elevated in the serum 
of ret transgenic mice with macroscopical tumors as compared to non-transgenic 
littermates (P < 0.05; Fig. 17.2 C). 
To investigate a direct effect of these tumor-derived factors on DCs, supernatants 
from cultured Ret melanoma cell (Ret conditioned medium, Ret-CM) was mixed with 
the culture medium (50%, v/v) and used for the DC generation from the BM 
precursors of wild type mice. As shown in Fig. 17.2 D, DCs generated under these 
conditions secreted significantly lower amounts of IL-12p70 (P < 0.05) upon LPS 
stimulation than DCs generated in the presence of normal DC medium. Furthermore, 
after adding neutralizing antibodies for IL-6 or VEGF or TGF-β1 to the DC medium 
supplemented with Ret-CM, we found a significant increase in IL-12p70 production 
by LPS-stimulated DCs as compared to DCs generated in the absence of these 
antibodies (P < 0.05; Fig. 17.2 D). 
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Figure 17.2. Tumor-derived cytokines and growth factors promote downregulation of IL-12 
production by DCs. (A) Total RNA was extracted from primary tumors, Ret melanoma cells 
and B16F10 melanoma cells. IL-6, TGF-β1 and VEGF expression was determined via 
RT-PCR using corresponding specific primers. Results from one representative experiment of 
three are shown. (B-D) Concentrations of IL-6 and VEGF at the protein level in tumor lysates 
and murine serum were measured using multiplex technology. Values in tumor lysates (B and 
C) expressed as pg/mg protein are plotted against the weight of each tumor sample. The 
correlation between the two variables was calculated using a linear regression analysis. Data 
in serum (D) are expressed as pg/ml and means ± SEM from 6-12 mice per group are depicted. 
* P < 0.05, differences between indicated groups. (E) DCs were generated from BM 
precursors of non-transgenic mice in the presence of supernatants from cultured Ret 
melanoma cells (Ret conditioned medium, Ret-CM; 50%, v/v) and of neutralizing antibodies 
for IL-6 (α-IL-6) or VEGF (α-VEGF) or TGF-β1 (α-TGF-β1) followed by LPS stimulation 
for 24h. IL-12p70 levels were tested in supernatants via ELISA. Results (means ± SEM) of 4 
independent experiments are expressed as pg/106 cells. * P < 0.05, differences between 
indicated groups.  
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17.3. p38 MAPK is strongly activated in DCs of ret transgenic mice with 
macroscopical tumors 
  Having demonstrated a critical importance of IL-6, VEGF and TGF-β1 for the 
acquirement of tolerogenic properties by DCs from tumor bearing mice, we then 
addressed the question which transcription factors regulating functions of these 
factors are responsible for the observed impairments. Phosphorylation levels of p38 
MAPK, STAT3, Smad3 and Erk1/2 MAPK were examined in freshly isolated spleen 
DCs by flow cytometry (Fig. 17.3 A). To prevent any artificial effect introduced 
during preparation, spleen cells were immediately fixed in PFA and permeabilized in 
ice-cold methanol after single cell suspension was made.  
 
Figure 17.3. Expression of transcription 
factors in DCs from melanoma bearing 
transgenic mice. Spleen cells from tumor 
bearing (ret tu), tumor free (ret) or wild type 
mice (WT) were fixed in paraformaldehyde and 
permeabilized in ice-cold methanol. (A) 
Expression of phosphorylated p38 MAPK 
(p-p38), STAT3 (p-STAT3), Smad3 (p-Smad3) 
and Erk1/2 MAPK (p-Erk1/2) was evaluated in 
CD11c+ DCs after staining with respective 
primary and secondary mAbs using flow 
cytometry. As a negative control (con), CD11c+ 
DCs stained only with secondary mAbs were 
used. Results from one representative 
experiment of three are shown. (B) 
Accumulative data for the transcription factor 
expression in spleen DCs (mean ± SEM) are 
expressed as mean fluorescence intensity (MFI) 
ratio (MFI of experimental samples/MFI of 
respective negative controls. *, P < 0.05, 
differences between indicated groups. 
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  We found that DCs from mice with macroscopical tumors displayed a significant 
upregulation in the expression of phosphorylated p38 MAPK, STAT3 and Smad3 as 
compared to those in DCs from wild type mice (P < 0.05), whereas the level of 
phosphorylated Erk1/2 MAPK remained unchanged (Fig. 17.3 A, B). Notably, p38 
MAPK activity shows the highest upregulation among studied factors. Therefore, we 
suspected that p38 MAPK might be a key regulator of the DC dysfunction in ret 
transgenic mice with macroscopical tumors. 
 
17.4. Inhibition of p38 MAPK activity normalized functions of DCs from 
tumor bearing ret transgenic mice 
We next assessed whether the inhibition of p38 MAPK activity could reverse the 
altered pattern of cytokine production shown by DCs from ret transgenic mice with 
macroscopical tumors. Ex vivo isolated spleen DCs were incubated in the presence of 
the p38 MAPK inhibitor SB203580 followed by stimulation with CpG. Suppression of 
the p38 MAPK activity was found to lead to the profound decrease of IL-10 
production (P < 0.05) as compared to untreated cells (Fig. 17.4 B). Furthermore, the 
IL-12/IL-10 ratio was also markedly increased (P < 0.01; Fig. 17.4 C). Thus, the 
cytokine secretion profile observed after treatment of DCs from tumor bearing mice 
with the p38 MAPK inhibitor was comparable to that for DCs from non-transgenic 
littermates. 
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Figure 17.4. Inhibition of p38 MAPK in DCs from tumor bearing mice restores their pattern 
of cytokine production and ability to stimulate T cells. (A-C) Spleen CD11c+ DCs were ex 
vivo isolated from tumor bearing (ret tu) or wild type mice (WT) using MicroBeads isolation 
kit, incubated with o without an inhibitor of p38 MAPK SB203850 (10 μM) for 1h and 
stimulated with CpG1668 for another 24h followed by measurement of IL-12p70 (A) and 
IL-10 (B) in supernatants using ELISA as well as calculation of IL-12p70/IL-10 ratio (C). 
Data are mean ± SEM from five independent experiments. *P < 0.05, differences between 
indicated groups. (D) Ex vivo isolated spleen DCs were incubated with or without SB203580 
during the loading with the OVA-peptide SIINFEKL for 1h. After extensive washing, DCs 
were co-cultured with CD8+ T cells isolated from OT-I mice for 3 days followed by 
measurement of IFN-γ levels in supernatants by ELISA. Means ± SEM from three 
independent experiments are depicted. *P < 0.05, differences between indicated groups. 
 
We further examined if the p38 MAPK inhibitor could restore impaired capacity of 
DCs from ret transgenic mice with macroscopical tumors to stimulate T cells. Freshly 
isolated spleen DCs were loaded with the peptide SIINFEKL in the presence of 
SB203580. After washing out the inhibitor, tumor DCs were co-cultured for 3 days 
with CD8+ T cells isolated from spleens of OT-I mice followed by the measurement of 
IFN-γ in the supernatant by ELISA. As shown in Fig. 17.4 D, DC pretreatment with 
69 
Results 
the p38 MAPK inhibitor was found to reconstitute IFN-γ production by T cells to the 
level detected after stimulation with normal DCs. Therefore, inhibition of p38 MAPK 
in DCs from tumor bearing mice resulted in the normalization of IL-12 and IL-10 
production as well as in the restoration of DC ability to stimulate OT-I CD8+ T cells.  
  In conclusion, our findings provide evidence that DC dysfunction in ret transgenic 
spontaneous melanoma mouse model can be induced by tumor-derived factors such as 
VEGF, IL-6 and TGF-β. Constitutive activation of p38 MAPK by these factors may 
result in a tolerogenic cytokine profile of DCs with low IL-12 and high IL-10 
secretion levels, which led to the impairment of antitumor T-cell mediated responses. 
Suppression of the p38 MAPK activity in DCs from tumor bearing mice can 
reconstitute their impaired cytokine pattern and capability to stimulate T cells 
suggesting a crucial role of p38 MAPK activity in the generation of tolerogenic DCs 
in ret transgenic tumor bearing mice. 
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IV. Discussion 
 
18. Reduction of DCs in lymphoid organs and accumulation of 
immature DCs in primary tumors of ret transgenic mice 
A significant decrease in total DC numbers was observed in the spleen and bone 
marrow of ret transgenic mice during tumor progression as compared to wild type 
mice or tumor free ret transgenic mice. The earliest report demonstrating a decline in 
Langerhans cells (skin DCs) during human melanoma progression is given by Stene et 
al. in 1988 (198). Later on, numerous publications showed that the number of DCs 
could be dramatically reduced in the periphery blood of patients with different types 
of tumors, such as lung cancer, squamous cell carcinoma of the head and neck, 
myeloma, invasive breast cancer, leukemia and hepatocellular carcinoma (40, 41, 43, 
46, 199, 200). Moreover, the presence of metastases resulted in a more profound 
decrease in numbers of circulated peripheral blood DCs in cancer patients (46, 47). In 
agreement with these reports, we demonstrated a significant decrease in DC amounts 
in metastatic lymph nodes from ret transgenic tumor bearing mice as compared to 
those in non-metastatic lymph nodes from the same mice or animals of control 
groups. 
A decrease of DC numbers in cancer patients can be induced by several 
mechanisms. One of them is the induction of apoptosis in DCs and their precursors. In 
vitro and in vivo studies demonstrate that DCs undergo apoptosis after interacting with 
cancer cells or soluble tumor-derived factors (49-52). Tumor induced DC apoptosis 
has been reported to be mediated by cytochrome c release, which further leads to 
cytoplasm shrinking, caspase-3 activation, upregulation of pro-apoptotic protein Bax 
and down-regulation of anti-apoptotic proteins Bcl-xL and Bcl-2 (49-51). Furthermore, 
growth of RM-1 prostate cancer cells could be significantly inhibited in mice treated 
intratumorally with DCs which were transduced with murine Bcl-xL gene (50). Other 
anti-apoptotic molecules are also shown to be able to inhibit tumor-mediated DC 
apoptosis, such as Fas associated death domain (FADD)-like ICE inhibitory proteins 
(FLIP) which blocks binding of procaspase-8 to FADD (52). In addition to the 
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cell-cell contact mechanism, induction of DC apoptosis can be induced by some 
tumor-derived factors, like IL-10, nitric oxide (NO), TGF-β, and gangliosides. For 
example, tumor-derived TGF-β1 can induce apoptosis of DCs in sentinel lymph nodes 
without evidence of metastasis in patients with non-small cell lung carcinoma and 
thereby facilitate metastasis within those lymph nodes (201, 202). In our experiments 
with co-incubation of normal spleen DCs with Ret melanoma cell conditioned 
medium from these cells, we were not able to demonstrate a substantial apoptosis rate 
in DCs (data not shown). 
Decreased numbers of total DCs could also be attributed to the inhibition of their 
generation from precursors. Impairment of differentiation from hematopoietic 
progenitor cells can be induced by tumor-derived factors. It has been reported that 
growth factors and cytokines like VEGF, M-CSF, TGF-β, IL-6 and IL-10 produced by 
human and mouse tumor cells could suppress maturation of DCs from CD34+ 
precursors in vitro (66, 67, 75, 85, 95). In particular, tumor-derived VEGF affected 
early stage of DC maturation in the bone marrow in vivo (85). IL-10, IL-6 and TGF-β 
profoundly affected phenotype and function of DCs in patients with advanced 
pancreatic carcinoma (203). 
Therefore, DC differentiation could be blocked at a certain stage. It is known that 
mature DCs are characterized by high levels of costimulatory molecules like CD80, 
CD86 and CD40. Investigating these markers on DCs from tumor bearing transgenic 
mice, we found a significant decrease in numbers of mature DCs expressing CD40, 
CD80 and CD86 in all studied lymphoid organs. Moreover, the growth of primary 
melanomas correlated with the accumulation of TIDCs with the immature phenotype. 
Blocking of normal DC differentiation and maturation may lead to the accumulation 
of cells with properties of myeloid derived suppressor cells (MDSCs). This 
heterogeneous population of myeloid cells consisting of monocytes/macrophages, 
granulocytes and DCs at different stages of differentiation and expressing various 
surface markers has been recently found to induce a dramatic suppression of T cell 
functions in mouse tumor models and in cancer patients (204-207). However, it still 
remains to be determined if the enrichment of MDSCs can directly lead to the loss of 
DCs in lymphoid organs of ret transgenic tumor bearing mice.  
  Another explanation of decreased DC numbers in lymphoid organs could be their 
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migration to tumors. After antigen uptake, immature DCs are activated and gain the 
mature phenotype and function. In addition to the DC elimination by apoptosis, tumor 
cells utilize other mechanisms to escape from DC-mediated immununosurveillance. 
For example, tumor-derived VEGF and β-defensins recruited immature DCs from BM 
to the tumor microenvironment and transformed them into endothelial-like cells that 
engaged in vasculogenesis and functioned as promoters of tumor progression (208). 
TGF-β and IL-10 secreted by tumor-derived CD4+ CD25+ Tregs could block the 
maturation of tumor infiltrating DCs by markedly down-regulating their costimulatory 
molecule expressions (113). In ret transgenic mice with macroscopical tumors, it was 
found using flow cytometry that the percentage of TIDCs showed a positive linear 
correlation with the tumor weight (r2=0.18, P <0.05), indicating an accumulation of 
DCs in tumors during melanoma progression. However, in agreement with the above 
mentioned publications TIDC maturation was blocked at the immature stage, because 
the percentage of CD40 expressing DCs in TIDCs decreased with the elevation of 
tumor weight (r2=0.31, P <0.05). Further immunohistochemistry study needs to be 
done to investigate the localization of TIDCs and their interaction with other host 
cells. 
In ret transgenic mice with macroscopical tumors, numbers of DCs in metastatic 
lymph nodes decreased significantly compared to non-metastatic ones. One 
explanation of these findings is that tumor microenvironment in metastatic lymph 
nodes induces DC apoptosis in situ. Another reason could be the link to the disability 
of DC homing to lymph nodes. After taking up tumor associated antigen from tumor 
regions, homing of mature DCs to tumor draining lymph nodes depends on the 
surface expression of certain chemokines and chemokine receptors (209). Therefore, 
further work needs to be done to investigate whether chemokine receptors, such as 
CCR7, are differently expressed on DCs from metastatic lymph nodes as compared to 
non-metastatic lymph nodes from ret transgenic mice with macroscopical tumors.  
 
19. Tolerogenic cytokine profile and impaired T cell stimulation 
  DCs from ret transgenic mice with macroscopic tumors were found to be impaired 
not only quantitatively but also qualitatively. When stimulated ex vivo, DCs from ret 
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transgenic mice with macroscopic tumors showed higher expression of IL-10 and 
lower expression of IL-12p70. IL-12 has been described during last years to be a 
critical cytokine for T-cell stimulation and to promote DC maturation and survival 
(210). However, production of IL-12 by DCs could be downregulated by different 
tumor-derived factors. Bombesin-like peptide (BLP) secreted by human lung cancer 
cells downregulated IL-12 production by DCs (211). Gangliosides produced by 
various human tumor cells suppressed DC maturation and function by reducing IL-12 
secretion (212-214). Moreover, tumor-derived IL-10, IL-6 and TGF-β profoundly 
affected the function of DCs in patients with advanced pancreatic carcinoma in favor 
of DCs showing immature phenotype and impaired IL-12 production (203). 
  Function of DC precursors in ret transgenic mice with macroscopical tumors has 
also been affected by tumor cells or tumor-derived factors. Even being incubated in 
the medium for DC generation in vitro, these cells differentiated into DCs which 
expressed much lower levels of MHC class II molecule and produced significantly 
less IL-12 after LPS stimulation as compared to non-transgenic littermates. Similar 
data has also been shown in multiple myeloma patients (60). 
  Consistent with the data from cancer patients (48, 201, 211), DCs from ret 
transgenic mice with macroscopic tumors showed impaired capacity to stimulate 
naïve CD8+ cells from OT-I mice. Mechanisms of the suppressed T-cell activation by 
DCs from ret tumor bearing mice are still unclear and need to be further investigated. 
Zou et al. (143) reported that some DC subsets suppressed T-cell function by 
delivering inhibitory signals through binding of B7-H1, B7-H2 or B7-H3 molecules to 
their receptors on T cells. In addition, several research groups showed that the IDO+ 
DCs could suppress T-cell activation. For example, mouse PDCs downregulated T-cell 
responses through the upregulation of IDO (141). Moreover, Baban et al. (142) 
characterized the IDO+ CD19+ DCs suppressed T-cell function following CD80/CD86 
ligation by CTLA4 or TLR9 ligation. 
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20. Activation of p38 MAPK drives DCs to display tolerogenic 
pattern during melanoma development 
Having established that DCs in ret transgenic mice with macroscopic tumors were 
functionally tolerogenic, we focused on studying the mechanisms of the generation of 
tolerogenic DCs in ret transgenic mice. Using a multiplex technology, we found that 
primary tumors from ret transgenic mice produced several immunosuppressive 
cytokines and growth factors like IL-6, IL-10, VEGF, and TGF-β1 and all of them 
were detectable in cell lysate of tumor tissues. Moreover, level of VEGF in primary 
tumors showed a positive linear correlation with the tumor weight (r2=0.56, P <0.05). 
In addition, VEGF and IL-6 were found to be expressed at the mRNA level both in 
primary tumors isolated from ret transgenic mice and Ret melanoma cells, and both 
factors were detected in the culture medium of Ret melanoma cells. We observed also 
significantly upregulated serum levels of IL-6 and VEGF in transgenic tumor bearing 
mice. von Felbert et al. showed that IL-6 knockout in ret transgenic mice induced 
decrease of melanoma incidence as well as tumor sizes, indicating the role of IL-6 in 
tumor progression in ret transgenic mouse model (197). In our experiments, the 
application of neutralizing antibodies against IL-6, VEGF or TGF-β1 significantly 
reconstituted IL-12 production by DCs generated under Ret melanoma cell 
conditioned medium.  
Although a list of tumor-derived factors involved in the impairment of DC 
functions is getting longer, they may utilize similar transcription factors and protein 
kinases in their signaling pathways. Therefore, we investigated some key transcription 
factors involved in ΙL-6, VEGF and TGF−β signaling pathways in DCs. Compared to 
non-transgenic littermates or ret transgenic mice without macroscopic tumors, DCs 
from tumor bearing mice showed significantly higher levels of phosphorylated-p38 
MAPK, STAT3 and Smad3. In agreement with our data, Wang et al. showed that 
tumor-derived VEGF and IL-10 inhibited DC maturation through activation of STAT3 
in DCs (116). Moreover, inhibiting STAT3 signaling in DC progenitors has been 
shown to reduce accumulation of immature DCs by tumor-derived factors in vitro 
(117). Finally, ablation of STAT3 in hematopoietic cells enhances DC maturation in 
tumor-bearing mice and results in a multicomponent antitumor immunity (118). 
Erk1/2 MAPK has also been shown to play an important role in the upregulation of 
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IL-10 and the suppression of IL-12 production by DCs (124, 125). In addition, 
inhibition of Erk function restored the impaired function of DCs (125, 126). However, 
in DCs from ret transgenic mice, the expression of phosphorylated Erk1/2 MAPK 
were not changed significantly, suggesting the involvement of mechanisms other than 
Erk1/2 activation in the tolerogenic function of DCs in this mouse model.  
Constitutively activated p38 MAPK contributed to the high IL-10 production of ex 
vivo activated DCs from ret transgenic mice with macroscopical tumors, which 
resulted in impaired T-cell responses. Inhibition of p38 MAPK activity by its inhibitor 
in DCs from ret transgenic mice with macroscopical tumors significantly 
down-regulated IL-10 expression and normalized the imbalanced IL-12/IL-10 ratio. 
Furthermore, p38 MAPK inactivation in DCs from ret transgenic mice with 
macroscopical tumors up-regulated IFN-γ production by primed OT-I T cells. A role 
of p38 MAPK in DCs during tumor progression has been controversially discussed in 
recent publications. Escors et al. (215) demonstrated that constitutive activation of 
p38 MAPK in mouse DCs resulted in their maturation and in the stimulation of T-cell 
responses against clinically relevant tumor antigens. On the other side, in agreement 
with the findings reported here, Wang et al. (60) found that the phenotype and T-cell 
stimulatory capacity of monocyte-derived DCs in patients with multiple myeloma 
were considerably impaired and that they could be restored by inhibiting p38 MAPK 
activity in progenitor cells. In addition, suppression of p38 MAPK signaling in murine 
DCs enhanced their ability to produce IL-12, attenuated regulatory T cell induction 
and stimulated the antitumor therapeutic efficacy of DCs pulsed with tumor-specific 
antigens (134).  
Application of p38 MAPK inhibitors for melanoma immunotherapy in vivo will 
require a thorough examination of their effects on host T-cell anti-tumor reactions, 
since the role of p38 MAPK in these cells is not completely clear. While the p38 
activation was shown to be important for T-cell development and effector functions (), 
other publications demonstrated that its activity was a prerequisite for the induction of 
Treg suppressor functions (217) or for apoptotic CD8+ T-cell death (218). Anti-tumor 
effects of the p38 MAPK inhibitor in our melanoma murine model in vivo are 
currently under investigation. 
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21. Summary  
  In the present work, we investigated the mechanisms of DC dysfunction during 
spontaneous melanoma development in ret transgenic mice. Animals with 
macroscopical tumors showed significantly reduced numbers of total DCs and mature 
DCs in the lymphoid organs, which may lead to insufficient stimulation of anti-tumor 
T-cell responses. An accumulation of immature DCs in tumors suggests that tumor 
microenvironment could block DC maturation and their migration to draining lymph 
nodes. Not only the phenotype but also DC functions were affected during tumor 
progression. DCs from tumor bearing mice displayed a tolerogenic cytokine profile 
(higher level of IL-12 and lower level of IL-10) and showed the impaired capacity of 
T-cell stimulation. Moreover, function of DC precursors in BM of tumor bearing mice 
was affected by tumors, and DCs generated in vitro from these precursors showed a 
tolerogenic pattern.  
Changes of DC functions in tumor bearing mice could be induced by tumor-derived 
factors such as IL-6, VEGF and TGF-β through activation of p38 MAPK. 
Suppression of p38 MAPK activity by a specific inhibitor could down-regulate IL-10 
production and reconstitute T-cell stimulation capacity of DCs from ret transgenic 
mice with macroscopical tumors. 
  In conclusion, our findings provide evidence that constitutive activation of p38 
MAPK is responsible for turning of DCs to display a tolerogenic profile in the process 
of melanoma development. Suppression of the p38 MAPK activity in DCs from ret 
tumor bearing mice can reconstitute their impaired cytokine secretion pattern and 
ability to stimulate T cells suggesting thereby that such normalization of signaling 
pathways in DCs could represent an effective immunotherapeutic strategy in 
melanoma patients.  
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VI. Abbreviations: 
 
A  
APC  antigen-presenting cell 
 
B 
BSA  bovine serum albumin 
bp  base pair 
 
C 
CCL  chemokine ligand 
CCR  chemokine receptor 
CD  cluster of differentiation 
cm  centimeter 
Con A  Concanavalin A 
CTL  cytotoxic T lymphocyte 
°C  degree Celsius 
 
D 
DC  dendritic cell 
DNA  deoxyribonucleic acid 
 
E 
EDTA  ethylenediaminetetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
ELISPOT enzyme-linked immunosorbent spot  
 
F 
FACS  fluorescent activated cell  sorting 
FCS  fetal calf serum 
FITC  fluorescein-5-isothiocyanate 
FSC  forward scatter 
 
G 
g  gramm 
g  acceleration due to gravity, 
  g = 9,81m/s2 
GM-CSF granulocyte/macrophage  colony stimulating factor 
 
H 
h  hour 
HRP  horseradish peroxidase 
H2O  water 
 
I 
IDO  indoleamine 2,3-dioxygenase 
IFA  incomplete Freund’s adjuvant 
IFN  interferon 
Ig  immunglobulin 
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IL  interleukin 
 
L 
l  liter 
 
M 
MAA  melanoma-associated antigen 
MDCs  myeloid dendritic cells 
MHC  major histocompatibility complex 
min  minute 
M  molar (mol/l) 
mM  millimolar 
ml  milliliter 
mg  milligramm 
mm  millimeter 
µl  microliter 
µg  microgramm 
mRNA  messenger RNA 
 
N 
NK cells natural killer cells 
nm  nanometer 
N  number 
 
O 
Ova  ovalbumin 
 
P 
%  procent 
PBS  Phosphate Buffered Saline  
PCR  Polymerase chain reaction 
PE  Phycoerythrin 
Pen/Strep Penicillin/Streptomycin 
PDCs  plasmacytoid dendritic cells 
pg  pikogramm 
 
R 
RNA  ribonucleic acid 
rpm  rounds per minutes 
RT  room temperature 
 
S 
SSC  side scatter 
 
T 
TCR  T-cell receptor 
TGF  transforming growth factor 
TNF  tumor necrosis factor 
Treg  regulatory T cell 
TRP  tyrosinase related protein 
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V 
VEGF  vascular endothelial growth factor 
V  volt 
v/v  volume per volume 
 
W 
WT  wild type 
w/v  weight per volume 
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